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In recent years, we came to realize that obesity, broadly
defined as increased body mass index or increased total body
fat, is not necessarily associated with metabolic dysfunction
and greater risk for cardiometabolic disease. In fact, there
are several obese persons who are “metabolically healthy,” as
there are nonobese persons who are “metabolically abnor-
mal.” Although the reason(s) underlying this phenomenon
are still not entirely clear, a number of studies conducted over
the past several years indicate that the anatomical location
of excess fat is more important than total body adiposity in
determining metabolic outcomes.
Ectopic fat accumulation, particularly in the liver, is
frequently observed in obese persons and is strongly asso-
ciated with metabolic dysfunction, including multiorgan
insulin resistance and dyslipidemia. Intrahepatic fat, possibly
more than visceral or intramyocellular fat, may thus be a
prominent factor modifying the metabolic risk associated
with increasing whole-body adiposity. However, cause-and-
effect relationships have not yet been established, and it is
also possible that intrahepatic triglyceride content is not a
determinant but merely a marker of metabolic health.
Understanding the regulation of fat accumulation in
the liver will thus have important implications in both
research and clinical practice. Little is known regarding the
specific effects of lifestyle factors such as diet and exercise
in regulating the accumulation of fat in the liver and its
depletion thereof. In this special issue, we have invited a few
papers in an attempt to partly fill this gap in our knowledge.
In the first paper of this issue, “Putative factors that
may modulate the effect of exercise on liver fat: insights
from animal studies,” several studies in animals are reviewed
in order to highlight putative factors that may modulate
the effect of exercise on liver fat. This includes the fat
content of the diet (exercise appears to be more effective
under high-fat feeding), the role of concurrent exercise-
induced loss of body weight or visceral fat, sex (males
versus females), prandial status (fasted versus fed), and
the duration of training, as well as the time elapsed from
the last bout of exercise. The potential importance of
these factors in modifying the exercise-induced changes in
liver fat has not yet been formally tested in man, thereby
providing a wide array of opportunities for future research.
The second paper of this issue, “Nafld, estrogens, and
physical exercise: the animal model,” focuses on the effects
of exercise on liver fat in relation to estrogen availability.
Estrogen deficiency, such as that occurring naturally after
menopause in women, is strongly associated with fatty
liver in animals. Exercise training exerts an estrogenic-
like effect on the expression of genes involved in hepatic
lipid metabolism and is a powerful means for preventing
liver fat accumulation in estrogen-deficient animals. The
third paper of this special issue, “Dietary conjugated linoleic
acid and hepatic steatosis: species specific effects on liver and
adipose lipid metabolism and gene expression,” reviews the
effects of dietary conjugated linoleic acid on liver fat content
and hepatic and adipose tissue fatty acid metabolism in
animals. Conjugated linoleic acids, particularly the trans-
10, cis-12, lead to hepatic steatosis owing to increased de
novo lipogenesis and increased hepatic fatty acid uptake,
at rates far exceeding the rates of disposal of intrahepatic
fatty acids towards oxidation, esterification, and triglyceride
export.
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The fourth paper of this issue, “Effects of exercise training
on molecular markers of lipogenesis and lipid partitioning in
fructose-induced liver fat accumulation,” examines the effects
of exercise training on liver fat in starved and subsequently
fructose-refed animals. Fructose, a simple sugar, is a potent
dietary trigger for liver fat accretion. Exercise training in this
model is not able to reverse the fructose-induced changes
in lipogenic enzymes and does not reduce intrahepatic
fat content. Thus, contrary to the large body of evidence
demonstrating that exercise is effective in alleviating hepatic
steatosis induced by high-fat feeding, exercise is not able
to reverse the changes induced by fructose feeding. The
final paper of this special issue, “Exercise and omega-3
polyunsaturated fatty acid supplementation for the treatment
of hepatic steatosis in hyperphagic OLETF rats,” evaluates
the effects of exercise on a hyperphagic model of obesity,
with or without concurrent omega-3 polyunsaturated fatty
acid supplementation. Exercise training in this animal
model alleviates hepatic steatosis even under low-fat feeding
conditions, predominantly by increasing hepatic fatty acid
oxidation, whereas supplementation with omega-3 fatty
acids slightly increases liver-fat content and attenuates the
liver-fat-depleting effect of exercise. It is noteworthy that
omega-3 fatty acid supplementation in this study accounted
for only 3% of total dietary energy, whereas in several
previous studies showing that omega-3 fatty acids reduce
liver fat the supplement was administered at much greater
doses.
Research presented and reviewed in this special issue
not only highlights the independent effects of exercise and
diet on liver fat accumulation but also, more importantly,
raises the intriguing possibility of interactive effects between
exercise and diet on the mechanisms regulating liver fat
accretion and depletion. It seems that several dietary factors
are able to either augment or attenuate the intrahepatic
triglyceride-depleting effect of exercise.
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An increase in intrahepatic triglyceride (IHTG) content is the hallmark of nonalcoholic fatty liver disease (NAFLD) and is strongly
associated with insulin resistance and dyslipidemia. Although regular aerobic exercise improves metabolic function, its role in
regulating fat accumulation in the liver is incompletely understood, and human data are scarce. Results from exercise training
studies in animals highlight a number of potential factors that could possibly mediate the effect of exercise on liver fat, but none
of them has been formally tested in man. The effect of exercise on IHTG content strongly depends on the background diet, so
that exercise is more effective in reducing IHTG under conditions that favor liver fat accretion (e.g., when animals are fed high-fat
diets). Concurrent loss of body weight or visceral fat does not appear to mediate the effect of exercise on IHTG, whereas sex (males
versus females), prandial status (fasted versus fed), and duration of training, as well as the time elapsed from the last bout of
exercise could all be affecting the observed exercise-induced changes in IHTG content. The potential importance of these factors
remains obscure, thus providing a wide array of opportunities for future research on the effects of exercise (and diet) on liver fat
accumulation.
1. Introduction
Excessive accumulation of fat in the liver, that is, intrahepatic
triglyceride (IHTG), is associated with increased prevalence
rates of and risk for dyslipidemia, diabetes, and cardiovascu-
lar disease [1–3]. Data from epidemiological as well as
metabolic studies indicate that increased IHTG content is
accompanied by insulin resistance and dysregulation of lipid
metabolism [4–6]. Exercise is known to improve metabolic
function [7, 8]; however its effects on IHTG remain elusive
[9, 10]. Data from studies in humans are scarce and not
entirely consistent [11]. In this paper, the results from a
number of animal studies are briefly reviewed in an attempt
to highlight putative factors that may modulate the effect of
exercise on IHTG content.
2. Exercise Training in Animals
Many studies have evaluated the effect of aerobic exercise
training on IHTG content in rodents; their design varies in
terms of sex, strain, background diet, training duration, the
prandial status, and the time of assessment after the last
bout of exercise (Table 1) [12–37]. Results are largely heter-
ogeneous, but a crude analysis of the data suggests that en-
durance training decreases IHTG (median: −16%, range:
−92% to +97%, n = 50 studies; Table 1). Most frequently
[14, 16, 18, 20, 26, 31, 35] but not always [15, 17, 34, 37],
exercise has been shown to be more effective in reducing liver
fat or attenuating its accretion in animals fed high-fat rather
than standard, low-fat diets (median decrease: 25% and 14%,
resp., Figure 1(a)). This is consistent with data from human
studies, in which exercise training appears to be more potent
in reducing IHTG in subjects with increased baseline IHTG,
for example, subjects with NAFLD, type II diabetes, or the
elderly [11].
The reasons why exercise is more effective in reducing
IHTG on high-fat than low-fat diets are not entirely clear
but are likely related to the hepatosteatotic effect of high-fat
feeding. Fat is mainly stored asmicrovesicles (<1 μm2) within
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Figure 1: Factors that may affect changes in liver fat in response to exercise training in animals. Exercise-induced changes in intrahepatic
triglyceride content (Δ-IHTG) are shown for: (a) animals fed high fat or standard chow (low fat) diets; (b) animals that experienced weight
loss (or attenuated weight gain) or not; (c) male or female animals; (d) fasted or fed animals; (e) animals trained for longer or shorter periods
of time; (f) animals examined within one day from the last bout of exercise or later during recovery. Box plots have been constructed using
average changes in liver fat (% difference relative to sedentary controls) for each group of animals in the studies depicted in Table 1, and
illustrate median, first, and third quartiles, minimum and maximum values, as well as potential positive and negative outliers.
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hepatocytes, whereas the high-fat diet-induced hepatic stea-
tosis occurs via accumulation of macrovesicles (>1 μm2)
[18, 38]. Endurance training has been shown to completely
prevent the high-fat diet-induced hepatic steatosis [18, 38],
that is, the hepatocyte surface area occupied by the lipid
vacuoles, solely by reducing the number of lipid vacuoles in
all sizes between 1 and 10 μm2 (i.e., macrovesicles), without
affecting the number of vacuoles of surface area <1 μm2 (i.e.,
microvesicles) [18]. Hence exercise may have less of an effect
when on low-fat diets, not only because of lower total IHTG
content, but also because most of this fat (∼75%) is stored in
microvesicles, not macrovesicles. Amore pronounced IHTG-
depleting effect of exercise has also been observed under
other conditions that favor the development of fatty liver,
such as overfeeding [34], ovariectomy [28], ethanol ingestion
[39], or tumor-bearing [24]. Apart from the fat content of the
background diet, the type of dietary carbohydrate [12], pro-
tein [25], and fat (i.e., saturated or unsaturated fatty acids)
[22], as well as the feeding pattern (ad libitum or paired) [12]
do not appear to affect, at least not in a major way, the
exercise-induced change in IHTG content.
The collective of available data in animals highlights a
number of other putative factors that may modulate the ef-
fect of exercise on liver fat; however, none of these factors has
been formally tested using rigorous experimental designs.
Concurrent weight loss or attenuated weight gain is not
likely critical for the exercise-induced depletion of IHTG
to manifest, albeit they may lead to greater reductions in
liver fat when compared to no weight loss or similar weight
gain (median decrease: 27.5% and 14%, resp., Figure 1(b)).
However, just like in humans [11], loss of visceral adipose
tissue mass with exercise training is not necessarily coupled
with a corresponding decrease in liver fat [16, 18, 28, 37].
Likewise, human studies have shown that exercise-induced
reductions in IHTG content can occur in the absence of
changes in total body fat [40] or even visceral adipose tissue
[41].
Exercise may be more effective in reducing IHTG content
in males than in females (median decrease: 25% and 14%,
resp., Figure 1(c)), in fasted (≥6 h) than in fed animals
(median decrease: 31% and 11%, resp., Figure 1(d)), and
after longer (≥8wk) than shorter interventions [34] (median
decrease: 24% and 14%, resp.; Figure 1(e)). The time elapsed
from the last bout of exercise (≤24 h or ≥36 h) may also
mediate the observed changes in IHTG (median decrease:
24% and 13.5%, resp., Figure 1(f)), suggesting that even
acute exercise could affect liver fat. However, relevant infor-
mation is scarce and inconclusive. A single bout of aerobic
exercise (30–60min) did not affect IHTG content, measured
immediately after exercise, in female rats [42] but caused a
∼30% decrease in male rats [43] of the same strain, under
both standard and high-fat feeding conditions. This is in line
with data from exercise training studies in animals raising the
possibility that males may be more sensitive to the IHTG-
reducing effect of exercise than females (Figure 1(c)), as
well as with recent observations in humans [44]. Studies
in which male rats were exercised until exhaustion provide
conflicting results, some observed a mild [45] or marked
[46, 47] increase in hepatic steatosis whereas others found
a decrease of 30–60% [48] at the end of exercise.
3. Detraining after Regular Exercise
If regular exercise reduces liver fat, cessation of exercise
should lead to an increase in IHTG content. Only a few
animal studies have evaluated the effect of detraining on liver
fat accumulation, and all have demonstrated that cessation of
regular exercise (after 6–16 weeks of training) for a short (2-
3 days) or a long (6 weeks) period of time is not associated
with any significant changes in IHTG content compared with
the trained state (i.e., before discontinuation of exercise)
when animals are fed a standard low-fat diet [28, 36, 49, 50].
Furthermore, detraining for 2–7 days does not alter the
total number of hepatocyte lipid vacuoles and their size,
even though it does activate precursors and processes in
the liver known to initiate steatosis (e.g., decreased mito-
chondrial oxidative capacity, increased expression of de novo
lipogenesis proteins, and increased malonyl CoA levels) [49].
Interpretation of detraining data is not straightforward,
though. It is possible that this lack of an effect of detraining
relates to the lesser potency of exercise in reducing liver fat
content in animals fed standard low-fat diets (Figure 1), so
that changes after detraining are similarly less pronounced.
For instance, two [28, 36] out of three studies that reported
no effect of detraining on liver fat also failed to observe a
training-induced decrease in IHTG content, suggesting that
training and detraining have no effect on liver fat accumu-
lation under low-fat feeding conditions. Whereas one study
[49] did observe a training-induced decrease in liver fat in
rats fed a low-fat diet but found no changes after detraining,
implying that the IHTG-depleting effect of regular exercise
is long-lived and is not readily reversed by detraining. Still,
compared with sedentary, never-exercised counterparts,
detrained animals appear to be relatively protected frommild
hepatic steatosis induced by 2 weeks of high-fat feeding [36],
but not from the development of frank fatty liver 6 weeks
after ovariectomy [28], even though cessation of exercise
training in ovariectomized rats resulted in a nearly 40%
increase in IHTG content compared with ovariectomized rats
who did not stop exercising [28]. It is thus possible that the
relevant molecular and biochemical adaptations to exercise
are readily reversed when the exercise routine is interrupted
(<1 week), however, changes in IHTG manifest later in
time and only when strong triggering factors for liver
fat accretion coexist, such as high-fat feeding or ovar-
iectomy. Support for this notion is provided by an earlier
study, where detraining resulted in a striking increase in
IHTG content only when animals were subjected to starva-
tion and refeeding [50].
4. Conclusion
The effect of exercise on IHTG content has recently attracted
much scientific interest in light of the apparent detrimental
metabolic effects of excessive liver fat accumulation. Al-
though the results from a few studies in human subjects
are promising, as exercise appears to reduce IHTG [11], the
importance of the factors highlighted herein on the basis
of studies in animals has never been evaluated in man.
Future studies should at least control for—in order to avoid
Journal of Nutrition and Metabolism 7
confounding—or directly investigate the role of these factors
in affecting the exercise-induced changes in liver fat content.
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One segment of the population that is particularly inclined to liver fat accumulation is postmenopausal women. Although
nonalcoholic hepatic steatosis is more common in men than in women, after menopause there is a reversal in gender distribution.
At the present time, weight loss and exercise are regarded as first line treatments for NAFLD in postmenopausal women, as it is
the case for the management of metabolic syndrome. In recent years, there has been substantial evidence coming mostly from the
use of the animal model, that indeed estrogens withdrawal is associated with modifications of molecular markers favouring the
activity of metabolic pathways ultimately leading to liver fat accumulation. In addition, the use of the animal model has provided
physiological and molecular evidence that exercise training provides estrogens-like protective effects on liver fat accumulation and
its consequences. The purpose of the present paper is to present information relative to the development of a state of NAFLD
resulting from the absence of estrogens and the role of exercise training, emphasizing on the contribution of the animal model on
these issues.
1. Introduction
Liver is particularly vulnerable to ectopic fat accumulation
that results in NAFLD characterized by hepatic lipid accu-
mulation (5 to 10% per weight) in the absence of significant
alcohol consumption [1]. In recent years, there has been
increasing evidence that NAFLD by itself has important
metabolic implications. Some authors refer to NAFLD as
“insulin resistance associated steatosis” since all components
of the metabolic syndrome correlate with liver fat accumu-
lation independently of obesity [2]. NAFLD is becoming a
risk factor for diabetes and cardiovascular diseases (CVDs)
independently of insulin resistance, metabolic syndrome,
plasma lipid levels, and other usual risk factors [3, 4]. NAFLD
has also been shown to predict both type 2 diabetes and CVD
independent of obesity. In addition, hepatic steatosis by itself
is associated with a proatherogenic lipid profile and increased
production of proinflammatory markers [5, 6].
The general association between NAFLD and CVD
was established by the fact that the liver is involved in
regulating/secreting numerous CVD risk factors, notably the
cytokine tumor necrosis factor-alpha (TNF-α), an acute-
phase protein CRP, glucose, lipoproteins, coagulation factors
(plasminogen activator inhibitor-1), and a substance which
increases blood pressure (angiotensin II) [7]. These authors
claim that “hepatocytes are the last cells to be involved in the
progressive chain of fat accumulation and probably the first
cells to tell us that something is wrong”.
The exact pathogenesis of hepatic lipid accumulation
seems to be very complex and only partially understood.
As a whole, the general mechanism of liver fat accu-
mulation involves an imbalance between lipid availability
(from circulating lipid uptake or de novo lipogenesis) and
lipid disposal (through fat oxidation or triglyceride-rich
lipoprotein secretion) [8, 9]. Excessive fat accumulation in
liver can occur as a result of increased fat delivery into
the liver (dietary fatty acids and plasma nonesterified fatty
acids derived from adipose tissue), increased fat synthesis
in liver, reduced fat oxidation, and reduced fat exportation
in the form of VLDL. Considering the complexity and
heterogeneity of the mechanisms involved, it is quite difficult
to imagine that it would be possible to identify a single
gene variation as the single cause of the disease [10].
Body fat, insulin resistance, oxidative stress, mitochondrial
dysfunction, cytokine/adipokine interplay, and apoptosis are
potential risk factors of NAFLD [10].
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One segment of the population particularly inclined
to increased hepatic fat accumulation is postmenopausal
women. Two thirds of postmenopausal women are consid-
ered overweight or obese and 43% present the metabolic
syndrome [11]. Recent evidence indicates that menopause
is indeed associated with the development of a state of
hepatic steatosis [12]. Population-based studies indicate that
nonalcoholic hepatic steatosis is more common in men than
in women. However, following menopause there is a reversal
in gender distribution so that NAFLD is more common in
women than in men [13]. In fact, it has been reported that
nonalcoholic liver steatosis is twice as common in post-
menopausal compared to premenopausal women, and that
hormonal replacement therapy decreases the risk of steatosis
[14]. Basic and clinical studies do support the hypothesis
that estrogens protect from the development of NAFLD
[15, 16]. In addition, alterations in body composition, fat
distribution, and/or hormonal or metabolic changes that
occur following menopause may influence the development
and progression of NAFLD [17].
It seems that hormone replacement therapy decreases the
risk of steatosis [14] as the prevalence of NAFLD is lower in
postmenopausal women taking hormone replacement ther-
apy than in women not taking it [18]. Nevertheless, although
hormone replacement therapy appears safe in NAFLD, it
is not recommended for liver protection because of the
increased risk of cardiovascular events [19, 20]. In a recent
review on NAFLD in older women, it was concluded that
at present, there are no specific or effective pharmacological
treatments available, and lifestyle modifications with weight
loss and exercise are regarded as first line treatments [21].
The purpose of the present review is to present informa-
tion relative to the development of a state of hepatic steatosis
with estrogens withdrawal and the role of physical exercise to
circumvent this phenomenon, emphasizing the contribution
of the animal model on these issues.
2. Estrogens Withdrawal in Animals:
Central and Peripheral Effects
2.1. Central (Extra-Hepatic) Effects of Estrogens Withdrawal.
Ovariectomy (Ovx) in animals leads to increased food
intake and body weight along with increased adipose tissue
and liver fat accretion [22–24]. Data from observational
and clinical trials support the fact that estrogens possess
favourable metabolic effects as estrogens treatment has been
shown to decrease body weight gain and fat accumulation
in both animals and humans [25, 26]. In addition to
increased food intake there is some evidence that energy
expenditure is decreased with estrogens deficiency. A 40%
reduction in ambulatory activity levels has been reported
after ovariectomy in mice [27]. There are, therefore, central
effects of estrogens withdrawal that are responsible for
increased food intake and decreased energy expenditure
resulting in adipocyte fat gain preferably in intra-abdominal
region.
Since hyperphagia is a well-known response to Ovx
and is prevented by estradiol replacement, many of the
effects attributed to estradiol may be explained primarily by
changes in food intake [28]. In fact, one view of Ovx-induced
obesity in rat is that estrogens removal leads to a marked
increase in body energy stores via increased energy intake
and food efficiency along with decreased energy expenditure,
which leads to increased energetic efficiency [24, 29]. This
contributes to weight gain, especially as visceral or intra-
abdominal fat, as observed in Ovx animals [30] and in
women during and after menopause [31, 32]. Consequently,
determinants of lipid metabolism such as liver triacylglycerol
level and adipose tissue lipoprotein lipase (LPL) activity are
altered in correspondence with an increased energy flux [29].
In other words, Ovx-induced increased energy efficiency
is accompanied by concomitant adaptations of peripheral
lipid metabolism that include the induction of pathways
implicated in fat accumulation [23]. Therefore, the central
effects of estrogens withdrawal on food intake and changes
in insulin levels and its efficiency of action may indirectly
affect liver fat accumulation in Ovx animals [24]. Central
effects of estrogens supplementation in Ovx rats have been
shown to lower food intake [33, 34], decrease adipose tissue
LPL activity [35], and increase adipose tissue lipolysis [36],
spontaneous physical activity [37], and energy expenditure
[34, 38]. With regard to the central effects of estrogens,
Picard et al. [24] postulated that Ovx induces obesity by
removing the catabolic actions of estrogens, which act upon,
yet poorly defined, central neuropeptidergic pathways that
regulate energy balance. On the whole, there is little doubt
that estrogens exert central effects that regulate feeding and
energy expenditure through direct actions on the hypotha-
lamus and/or through indirect actions by regulating adipose
hormones such as leptin, adiponectin, and resistin [39].
2.2. Peripheral (Intrahepatic Effects) of Estrogens Withdrawal:
Molecular Implications. In addition to the central effects,
it is now well recognized that almost all tissues are under
estrogenic influence in both men and women [40, 41].
Epidemiological and clinical evidence strongly suggest that
estrogens, in particular 17 β-estradiol, the most potent
and dominant estrogens in mammals, play an important
regulatory role in the metabolism and regional distribution
of adipose tissue [42–44]. Estrogens promote subcutaneous
fat depot after sexual maturation [43], while estrogens
deficiency leads to increased fat, predominantly in visceral
tissue [45]. It seems that estrogens control fat distribution
by changing the lipolytic response distinctly into the two
fat deposits, thus favouring fat accumulation in peripheral
depots at the expense of the visceral depot [45]. There is
also evidence that estrogens regulate LPL activity. It has
been shown in several studies that ovariectomy in female
rats results in increased adipose tissue LPL, while estrogens
replacement decreased LPL activity [44].
In recent years, it has become evident that estrogens’
role in adipose tissue biology and lipid metabolism may
be broader and more complex than initially appreciated. It
seems that active metabolic tissues, such as the liver, are
particularly sensible to estrogens effects in terms of different
functions including lipid metabolism. The molecular and
biological mechanisms underlying the metabolic actions
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Figure 1: Effect of energy restriction in Ovx rats to the same level
as food intake in intact rats on the hepatic TAG accumulation. n =
8/group. Sham: sham operated; Ovx: ovariectomized; OvxPF: Ovx
rats paired fed to the level of Sham rats. ∗Significantly different from
Sham P < 0.05; + Significantly different from Ovx P < 0.05. Taken
in part from Paquette et al. [30].
of estrogens in liver are weakly understood. Estrogens are
a steroid hormone mainly produced by ovaries whose
actions are predominantly mediated by genomic mecha-
nisms through its nuclear receptors (ER) α or β [46].
Outstanding advancements in recent years indicate that
estrogens action in vivo is complex and often involves
activation of cytoplasmic signalling cascades in addition to
genomic actions mediated directly through estrogens recep-
tors α and β. Estrogens may simultaneously activate distinct
signalling cascades that function as networks to coordinate
tissue responses [47]. These orchestrating distinct signalling
pathways which involve specific complexes of cytoplasmic
proteins might supplement or augment genomic effects of
estrogens that are attributable to transcriptional activation
by liganded receptors [48]. Therefore, it is not surprising
that estrogens have been shown to exert rapid non-genomic
biological actions through membrane bound subpopulations
of ERs [49–51]. Interestingly, D’Eon et al. [52] reported
novel genomic and non-genomic actions of estrogens that
promote leanness in Ovx animals independently of reduced
energy intake. In a recent review on estrogens regulation
of adipose tissue functions, it was reported that estrogens
reduce adiposity by promoting the use of lipid as fuel which
is recognized by the activation of pathways that promote fat
oxidation in muscle, by inhibition of lipogenesis in adipose
tissue, liver, and muscle and by improved rates of adipocyte
lipolysis [45]. The precise mechanism by which estrogens
affect these functions is still unknown.
Estrogens-deficient state in ovariectomized animals has
been repeatedly shown to result in a rapid liver fat accu-
mulation [30, 53, 54]. Hepatic steatosis also developed in
aromatase-deficient mice (ArKO; lacking the intrinsic ability
to produce estrogens) and is diminished after treatment
with estradiol [55]. Visceral obesity, metabolic syndrome
with insulin resistance, as well as hepatic steatosis are
the main features of the ArKO’s mouse phenotype [56].
Although many of the effects attributed to estrogens in the
pathogenesis of Ovx-induced fat gain may be explained to
a certain extent by the central effects of estrogens mostly
via changes in food intake, D’Eon et al. demonstrated
that estrogens reduced adiposity in Ovx rodents without
confounding differences in food intake [52]. Their data are
consistent with the phenotypes of both estrogens receptors-
α (ERKO) knock-out and ArKO mice, both of which exhibit
increased adiposity with no reported differences in food
intake [38, 57–59]. Moreover, the results of Beckett et al.
[60] suggest that estradiol regulates substrate metabolism
in ectopic tissues such as skeletal muscles independently of
changes in food intake. On the whole, it becomes evident that
the ovarian hormonal status has important ectopic effects
at the molecular level in peripheral tissues such as the liver
rather than only central effects on food intake and energy
expenditure. Accordingly, Fisher et al. [61] reported that
despite a similar food intake, Ovx-pair fed animals gained
markedly more weight than did Sham animals and nearly
as much as Ovx-ad libitum animals. Likewise, data collected
from our lab indicate that pair-feeding in Ovx rats does
not completely prevent liver fat accretion in rats (Figure 1).
Therefore, there must be factors other than food intake in the
pathogenesis of liver fat accumulation in estrogenic-deficient
state.
Some intrahepatic pathways leading to lipid infiltration
in estrogens deprived states have been investigated. Increased
lipid uptake by liver as a result of increased fatty acid flow
from circulation coming from intra-abdominal fat deposi-
tion attributed to the increased food intake after estrogens
withdrawal can primarily and partially explain hepatic fat
accumulation. The portal/fatty acid flux theory suggests that
visceral fat, via its unique location and enhanced lipolytic
activity, releases toxic-free fatty acids, which are delivered
in high concentrations directly to the liver [62]. However,
the portal/fatty acid flux theory has been questioned with
the observation that the bulk of portal vein free fatty acids
originate from subcutaneous adipose tissue in overnight-
fasted obese individuals [63]. Nevertheless, there is little
doubt that an increased arrival of lipids in situations of
increased food intake and/or increased lipolysis contributes
to liver lipid infiltration.
Disturbed regulatory mechanisms of lipids in the liver
resulting from estrogens deficiency have been reported to
play a role in liver fat accumulation. As estrogens levels
decline, there may be increased lipogenesis and reduced fatty
acid oxidation within the liver [17]. Liver de novo fatty
acid synthesis that may result in hepatic steatosis is mostly
regulated by three known transcription factors: SREBP-1c,
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ChREBP, and PPAR-γ [64–66]. SREBP1-c activates fatty
acid synthase (FAS) and stearoyl-CoA desaturase-1 (SCD-
1) genes that are responsible for lipogenesis in liver [64].
D’Eon et al. [52] investigated the expression of several genes
involved in the regulation of lipogenesis in the liver of Ovx
and Ovx with estrogens replacement mice. Similar to their
observations in adipose tissue, estrogens supplementation
in Ovx rats decreased hepatic expression of the lipogenic
gene SREBP-1c and its downstream targets ACC-1 and
FAS compared to Ovx control rats. Similarly, increased
lipogenesis in liver of Ovx rats was supported by changes
in the expression and protein content of the lipogenic
markers SREBP-1c and SCD-1 [67]. Furthermore, Na et
al. [68] reported that estrogens deficiency in high-fat fed
rats increased liver mRNA expressions of FAS and PPAR-
γ while decreasing mRNA levels of the oxidative marker
PPAR-α. In line with these reports, Ovx mice displayed
visible steatosis even in a state of pair-feeding that was
coincident with a remarkable elevation in hepatic PPAR-γ
gene expression and downstream target genes FAS and ACC
[68]. To confirm the role of estrogens in regulation of hepatic
lipid metabolism, it has been shown that 17-beta-estradiol
replacement in an animal model completely prevented the
accumulation of lipids in the liver of Ovx rats and normalized
the disturbed lipogenesis and lipid oxidation in liver [67, 69].
In addition to increased lipogenesis, a decrease in hepatic
gene expressions involved in lipid oxidation, such as PPAR-
α, was also reported in Ovx rats. PPAR-α is a receptor for
peroxisome proliferators that functions as a lipid sensor
that, when ineffective, can lead to reduced energy burning
resulting in hepatic steatosis [70]. A decrease in PPAR-α in
liver of Ovx rats has been reported [67]. Similar findings
have also been reported in liver of ARKO mice [71]. Finally,
Paquette et al. [72], using a physiological approach, reported
a decrease of 34% in the rate of fatty acid oxidation in isolated
hepatocytes of Ovx rats.
Besides lipogenesis and lipid oxidation, VLDL-TG pro-
duction and secretion under low estrogenic condition might
also be affected. In a study by Lemieux et al. [73] conducted
on female Sprague-Dawley rats treated with the estrogens
antagonist acolbifene, it was found that VLDL-TG secretion
rate and microsomal transfer protein (MTP) mRNA levels
were decreased by ∼25–29%. Very recent data from our
laboratory also revealed a decline in VLDL-TG production
and MTP mRNA and protein content in Ovx rats [53].
Taken together, it is clear that estrogens withdrawal can
have direct effects on hepatocytes and cellular constituents of
liver tissue (intrahepatic effects) as well as central effects on
food consumption, energy expenditure, and adipose tissue
fat deposition that jointly contribute to the overall effects of
liver fat accretion (Table 1).
3. NAFLD in Polycystic Ovary Syndrome
(PCOS) Women
As mentioned above, premenopausal women are protected
from the occurrence of CVD and NAFLD [16]. However,
following menopause there is a reversal in gender distri-
bution so that NAFLD becomes more common in women
than in men [13]. It seems that a normal balance between
androgens/estrogens ratio is required to maintain a proper
distribution of body fat and normal metabolism in men
and women [74]. For instance, hypoestrogenism in male
rats and men is associated with fatty liver and features of
the metabolic syndrome [16]. Similarly, hyperandrogenism
in women is associated with increased central adiposity,
insulin resistance, and increased risk of NAFLD [74]. Women
with PCOS are at increased risk of metabolic syndrome
and other complications such as type 2 diabetes and
NAFLD [75, 76]. According to the European Society for
Human Reproduction (ESHRE) and the American Society
of Reproductive Medicine (ASRM), a diagnosis of PCOS
requires two of the following three criteria: the presence of
oligoovulation or anovulation, biochemical or clinical signs
of hyperandrogenism, and the presence of polycystic ovaries
[77]. Gambarin-Gelwan et al. [78] reported the presence of
fatty liver in 55% of patients with PCOS, and nearly 40% of
the patients diagnosed with NAFLD were lean. The beneficial
effect of weight loss and exercise on liver fat accumulation of
PCOS patients has been observed in a case report [79].
4. Exercise/Diet Interventions in
Postmenopausal Women
More than 60% of American postmenopausal women are
overweight or obese [80] and as mentioned earlier, it is
well established that menopause is associated with weight
gain, unfavourable alterations in body composition (elevated
visceral fat deposition), and a state of hepatic steatosis [12,
81]. It seems that hormone replacement therapy (HRT)
alleviates the metabolic consequences of menopause [82–
84]. However, research on the safety of HRT is conflicting.
The Women’s Health Initiative in the United States in
2002 and the Million Women Study in the UK in 2003
reported evidence of increased risk of heart disease, stroke,
venous thromboembolism, and breast cancer with HRT in
postmenopausal women [85, 86]. In general, although short-
term use of HRT remains beneficial for severe menopausal
symptoms, the uncertainty with the risks/benefits of HRT
along with the well-publicized results of the above two
large-scale HRT trials, has led to the conclusion that HRT
will not protect future health in postmenopausal women
[87]. Therefore, women continue to seek alternative options
to improve their quality of life and reduce the risk of
heart disease, osteoporosis, and breast cancer during post-
menopause time [88].
Interestingly, the most research recommended corner-
stone prevention/treatment for weight gain, elevated visceral
fat deposition, and hepatic steatosis is weight loss through
lifestyle interventions including exercise and/or diet. In a
recent review, Zanesco and Zaros [89] reported that in an
attempt to reduce the incidence of CVD in postmenopausal
women, a variety of approaches has been used with conflict-
ing results. Nevertheless, the change in lifestyle has been pro-
posed as the most effective preventive action. This conclusion
confirms the important role played by exercise and nutrition
in the prevention and treatment of obesity, diabetes, and
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Table 1: Summary of the central and intrahepatic effects resulting in liver fat accumulation with estrogens withdrawal.
Central effects Intra-hepatic effects
CNS/hypothalamic effects Lipid uptake
(i) ↑ Food consumption
(ii)↑ Leptin secretion
(iii) ↓ Activity and energy expenditure
(i) Unknown (possible mechanism of upregulation of fatty acid
uptake via estrogens-dependent pathways, yet to be explored)
Lipid profile and adipose tissue effects Lipogenesis
(i) Absence of estrogens causes fat redistribution/gain
particularly increased intra-abdominal fat and altered lipid
homeostasis (portal/fatty acid flux theory)
(i) ↑ SREBP-1c and PGC1α
(ii) ↑ SCD-1
(iii) ↑ FAS
(iv) ↑ ACC
(v) ↑ PPAR-γ
Lipid oxidation
(i) ↓ PPAR-α
(ii) ↓HSL
(iii) ↓ Fatty acid β-oxidation
VLDL-TG production and secretion system
(i) ↓ VLDL-TG production in Ovx rats
(ii) ↓MTP and DGAT2
CNS: central nervous system; SREBP-1c: sterol-regulatory-element-binding-protein 1c; PGC1α: peroxisome proliferator-activated receptor gamma
coactivator-1 alpha; SCD-1: stearoyl-CoA desaturase-1; FAS: fatty acid synthase; ACC: acetyl-CoA carboxylase; PPAR-α, -γ: peroxysome proliferator-activated
receptor-alpha, -gamma; HSL: hormone-sensitive lipase; VLDL-TG: very low density lipoprotein-triglyceride; MTP: microsomal triglyceride transfer protein;
DGAT2: diacyl-glycerol acyltransferase-2.
CVD in postmenopausal women [90, 91]. Data from a 5-
year randomized clinical trial known as the Women’s Healthy
Lifestyle Project had previously demonstrated that weight
gain and increased waist circumference during the peri- to
postmenopausal period can be prevented by a long-term
lifestyle dietary and physical activity intervention [92].
One of the most important components of lifestyle is
physical activity which has been known for a long time to
be a powerful low-risk mean for the promotion of all aspects
of human health including menopause [93]. Postmenopausal
women might demonstrate a greater response to exercise
since it was shown that even small increases in physical
activity and exercise at the time of menopause can help
prevent the atherogenic changes in lipid profiles and the
weight gain experienced by these women [91]. Longitudinal
and cross-sectional studies have shown that physical activ-
ities, such as moderate-intensity sports/recreational activity
or biking and walking for transportation are associated with
lower body fat and less central adiposity in postmenopausal
women [81, 94, 95]. Moderate-intensity exercise (walking or
45min moderate-intensity aerobic activity 5 d/wk) can also
result in improvements in coronary/metabolic risk factors
such as insulin resistance in postmenopausal women [96–
98]. The results of a study by Hagberg et al. [99] even
indicated that numerous years of high-intensity endurance
training had a greater effect on total and regional body
fat values than HRT in postmenopausal women. Given
that obesity is extremely prevalent and difficult to treat,
prevention of weight gain after menopause is an important
health target. A successful model of weight gain prevention
has yet to be established [100]. In a longitudinal study,
Hagmar et al. [101] reported that former elite but still
active endurance female athletes had higher flow-mediated
vasodilatation, used as an indicator of endothelial function,
than control subjects. This latter study does not, however,
discriminate the previous exercise training conducted during
the reproductive period from the training conducted during
menopause. A response to this question may be tentatively
obtained from a recent study in Ovx animals in which it was
found that to be effective in reducing adipocytes and liver
fat accumulation, exercise must be conducted concurrently
with estrogens withdrawal [102]. On the whole, it seems
that postmenopausal women with high levels of physical
activity have lower body and abdominal fat and are less likely
to gain fat (total and abdominal) during menopause than
those with lower levels of physical activity [81]. Endurance
training has been reported to be very effective in reducing
intrahepatic triglycerides content in human (for a recent
review see [103]). More recently, a 12-month intensive
lifestyle intervention in patients with type 2 diabetes has
been reported to reduce hepatic steatosis by as much as 25%
[104]. However, information is lacking on the role of exercise
training specifically on prevention and/or reversal of hepatic
steatosis in postmenopausal women.
5. Exercise in the Animal Model of Menopause
Ovx animals can benefit from an exercise training program
with a reduction in fat gain [105]. In 2002, Shinoda et
al. [106] showed that exercise training exerts a strong
action upon reduction in body fat accumulation following
a decrease in estrogens levels. In spite of the reduction in
body fat, 8 wk of endurance exercise training in this study
did not reduce overall weight gain suggesting a compensatory
increase in muscle weight by training. This is an interesting
asset of exercise since food restriction protocols in Ovx
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rats have been known to be associated with a decrease in
muscle mass [107]. In this regard, it was shown that muscle
tissue hypertrophy induced by a progressive loading exercise
program has a stimulatory effect on bone mass in Ovx rats
[108].
A major concern of a reduction in estrogenic status
is insulin resistance. It is well known that environmental
factors such as aging, obesity, and physical inactivity are
linked to the development of a state of insulin resistance
and type 2 diabetes mellitus. Rationally, the prevalence
and progression of type 2 diabetes are likely to increase
in postmenopausal women. Several studies reported insulin
resistance in experimental animals after Ovx, which can be
reversed by HRT and exercise training although the results
have been somewhat conflicting [22, 109, 110]. One of the
best evidence of the effects of exercise training on estrogens
withdrawal-induced insulin resistance comes from the study
of Saengsirisuwan et al. [111]. These authors showed that
ovariectomy in female Sprague-Dawley rats resulted in the
development of a systemic metabolic condition presenting
the characteristics of the metabolic syndrome including
increased visceral fat content, abnormal serum lipid profile,
impaired glucose tolerance, and defective insulin-mediated
skeletal muscle glucose transport. Saengsirisuwan et al. [111]
also provided evidence that whole-body and skeletal mus-
cle insulin resistance is effectively corrected by endurance
exercise training alone and estrogens replacement alone.
Despite this and similarly to Choi et al. [112], they could
not find evidence that exercise training additively modulates
insulin action in Ovx animals that also received estrogens
replacement, suggesting that endurance exercise training
and estrogens may share common mechanisms to correct
defects in ectopic tissues caused by estrogens deficiency. This
concept is supported by the observations that transcripts
encoding estrogens signalling in skeletal muscle, cardiac
muscle, and liver are enhanced by regular exercise [113–115].
As previously mentioned, menopause is associated with
the development of a state of hepatic steatosis [12, 116],
which plays an important role in the development of insulin
resistance [117]. Ectopic fat in liver may be even more impor-
tant than visceral fat in the characterization of metabolic
obesity in humans [118, 119]. An alternative to counteract
liver fat accumulation with estrogens withdrawal may be
exercise training. It has been reported that exercise training
prevents fat accumulation in livers of high-fat fed rats [120,
121]. Recently, we reported evidence that endurance exercise
training conducted concurrently with estrogens withdrawal
did prevent liver fat accumulation in rats [102]. This latter
study is particularly interesting since it also showed that
if exercise is conducted only before the ovariectomy, there
was no protective effect of exercise on subsequent Ovx-
induced liver fat accumulation. On the other hand, if exercise
was started at the same time as Ovx was performed, liver
fat accumulation was prevented emphasizing the finding
that exercise must be conducted concurrently as estrogens
withdrawal to be effective. To explore mechanisms by
which exercise prevents liver fat accumulation in Ovx rats,
Pighon et al. [122] conducted a subsequent study in which
they measured the expression of several genes in liver. They
found that exercise training acts as estrogen supplementation
in properly decreasing several genes of lipogenesis (SREBP-
1c, ChREBP, SCD-1, ACC) as well as decreasing several
biomarkers of subclinical inflammation (IL-6, NFkB, TNFα)
in Ovx rats.
6. Resistance Training (RT) in
Postmenopausal Women
Weight loss achieved through restrictive diets often results
in negative effects on muscle mass [123]. In this regard,
resistance training seems to be a logical choice considering
its beneficial effects on muscular strength in postmenopausal
women [124]. It has been demonstrated that RT exercise
can be an effective substitute for hormone replacement
therapy in preventing menopause-related osteoporosis and
sarcopenia [125]. In addition to increasing muscle mass
and improving muscle function, RT has been reported to
induce decreases in total and abdominal fat [126, 127]. On
the other hand, there are studies that showed no reduction
in fat tissue with RT exercise [128]. Eight weeks of low
intensity, short duration RT program was not sufficient
to produce significant modifications in body composition
and blood lipid concentrations in postmenopausal women,
although it produced substantial improvements in muscle
strength [129]. In obese sedentary postmenopausal women,
it has been suggested that RT has the potential to ame-
liorate/prevent the development of insulin resistance and
may reduce the risk of glucose intolerance and non-insulin-
dependent diabetes mellitus [130]. In these subjects, RT
alone or in combination with a weight loss program (diet)
(RT+WL) improved muscular strength and insulin action
and glucose homeostasis. However, the same authors in a
subsequent study showed that body weight and fat mass did
not change with RT alone, but decreased with RT+WL [131].
Nevertheless, RT and RT+WL both increased fat-free mass
and resting metabolic rate in postmenopausal women [132].
Considering the fact that subjects in RT group were nonobese
and subjects in RT+WL group were obese postmenopausal
women, the authors suggested that RT may be a valuable
component of an integrated weight management program
in postmenopausal women. In a recent study conducted
in overweight and obese postmenopausal women, it was
reported than RT combined to caloric restriction was more
effective that caloric restriction alone in reducing fat mass
(%) and trunk fat mass [133]. Although, as for endurance
training, there is a paucity of information on the impact
of RT on NAFLD in postmenopausal, it seems that RT
constitutes an asset to overcome several of the deleterious
metabolic effects associated with menopause.
7. Resistance Training (RT) in Ovx Animals
In Ovx rats, Corriveau et al. found that an 8 wk program
of resistance training in conjunction with restrictive diet
reduced intra-abdominal fat depot and plasma-free fatty
acid levels and prevented liver fat accumulation [54]. It was
concluded that RT is an asset to minimize the deleterious
Journal of Nutrition and Metabolism 7
effects of ovarian hormone withdrawal on abdominal fat
and liver lipid accumulation in Ovx rats. Leite et al. [134]
also recently indicated the potential benefits of resistance
training as an alternative strategy to control the negative
effects of ovariectomy. Twelve weeks of strength training in
Ovx rats decreased fat content in liver, skeletal muscle, and
intra-abdominal adipose tissue and positively changed lipid
profile such as increasing HDL levels while decreasing total
cholesterol and LDL levels. In both of these studies, the RT
program consisted of climbing a vertical grill with weights
attached to the tail of rat.
Using the same design as Corriveau et al. [54], Pighon
et al. conducted two studies on liver and body fat regain
in Ovx rats using resistance training. In a first study [135],
they tested the hypothesis that substituting food restriction
by resistance training after a period of weight loss would
maintain the decrease in fat accumulation in liver and
adipose tissue that occurs with weight loss. We found that
cessation of an 8 wk food restriction regimen aimed at
lower body weight and fat accumulation in Ovx rats may be
substituted by a resistance training program (over 5 more
weeks), without causing any appreciable regain of fat in
liver and adipose tissue. Our group suggested that changing
from a food restriction regimen to a resistance training
program may be an interesting strategy to promote successful
long-term weight reduction in postmenopausal women. In a
second study, Pighon et al. [136] investigated the effects of
maintaining RT or food restriction on body weight regain,
fat mass, and liver lipid infiltration in Ovx animals previously
submitted to a food restriction + RT weight loss program.
We observed that maintaining only food restriction was the
most effective but that maintaining RT alone was an asset to
attenuate intra-abdominal and liver fat reincrease. Again we
suggested that the maintenance of only one component of
an RT+ food restriction weight loss program constitutes a
positive strategy to reduce body weight and fat mass relapse
in postmenopausal women.
8. Exercise and Weight Regain
It seems that maintenance of weight loss is a core problem
in the treatment of obesity, and long-term maintenance
of weight loss remains a challenge. A common treatment
for weight loss is food restriction or hypocaloric diet
therapy. Although interventions aimed at weight loss are well
supported [137], reductions in weight by dietary restriction
are typically modest and are increasingly viewed as an
unsustainable outcome of lifestyle modification [138, 139].
It thus seems that there is a high rate of recidivism after diet-
induced weight loss. One of the main underlying problems
in this matter appears to be the compensatory metabolic
responses to weight reduction which results in a strong drive
to regain lost weight [140, 141]. Such responses include
enhanced metabolic efficiency with a progressively increasing
appetite along with interrelated alterations like improved
insulin sensitivity and energetically favourable shift in fuel
utilization characterized by an increased preference for
carbohydrate oxidation at the expense of lipid oxidation
which may explain why successful weight reduction is so
hard to achieve [140]. MacLean et al. [142] believe that these
compensatory metabolic adjustments are part of an inter-
related group of adaptations in the homeostatic feedback
loop between the periphery and the central nervous system
that controls body weight. It seems that the homeostatic
feedback system defending body weight and adiposity is
fundamental to the metabolic drive to regain lost weight
[142, 143]. The positive aspect is that modification of this
biological predisposition is possible. Interestingly, exercise
training seems to positively alter this propensity and has been
shown to be important to successful weight maintenance
after weight loss programs [144, 145]. Levin et al. [146, 147]
reported that regular physical activity lowers the defended
level of weight gain and adiposity without compensatory
increase in intake and with a favourable alteration in
the development of the hypothalamic pathways controlling
energy homeostasis as compared to calorically restricted rats.
These authors suggested that exercise produces a different set
of regulatory signals from caloric restriction that resets the
homeostatic balance between energy intake and expenditure
toward defence of a lower level of weight gain and adiposity.
Body weight and fat mass gain and regain following
weight loss may be even more critical after menopause
since physiological withdrawal of ovarian hormones, by
itself, negatively affects the energy balance. Similarly to the
above discussion on weight regain, Nicklas et al. [148]
suggested that the poor success rate of food restriction
treatment in postmenopausal women may be due in part
to metabolic adaptations that occur in response to a long
period of negative energy balance such as declined fat
oxidation, resting metabolic rate, and adipocyte lipolytic
responsiveness which predispose the regain of body weight.
These authors showed that the addition of endurance
exercise to diet-induced weight loss program minimizes
these negative metabolic adaptations in postmenopausal
women. Similarly, substituting a walking training to a very-
low-energy diet in premenopausal obese women improved
maintenance of losses in weight and waist circumference and
prevented further clustering of metabolic risk factors [149].
As mentioned above, data on Ovx rats suggest that changing
from a food restriction regimen to an exercise training
program can be an interesting strategy to promote long-term
weight reduction in postmenopausal women [135].
9. Conclusion
It is becoming increasingly clear that once women reach
menopause in their life they are exposed to increasing risks
of developing complications due to a decrease in estrogens-
related protective effects. Among the protective effects of
estrogens, liver fat accumulation seems to be of primary
importance due to its important role in the development
of insulin resistance, atherosclerosis, and cardiovascular
diseases. Information relative to cellular and molecular
mechanisms using the animal model indicates that gene
expressions of molecules such as SREBP-1c, ChREBP, and
SCD-1 involved in the lipogenesis pathway are upgraded
with estrogens withdrawal, while molecular markers of
the oxidative pathway including CPT-1 and PGC-1 and
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molecular markers of VLDL production such as MTP and
DGAT-2 are reduced with estrogens loss [53, 122]. These
observations point to the direction that a reduction in estro-
gens production results in central effects such as an increase
in food intake and a reduction in energy expenditure, but
may also metabolically affect tissues such as the liver thus
resulting in ectopic fat accumulation. In a recent review
paper on NAFLD in older women [21], it was concluded
that there is no effective pharmacological treatment available
and that lifestyle modifications with weight loss and exercise
are regarded as first line treatment. Although there is a
lack of information on the role of exercise on liver lipid
infiltration during the premenopausal to postmenopausal
transition, data on the animal model clearly indicate that
exercise training exerts a powerful action in reducing liver fat
accumulation especially if exercise training is conducted at
the same time as estrogens withdrawals [102, 120]. Exercise
training seems to exert an estrogenic-like effect not only on
expression of genes involved in lipid accumulation but also
on expression of genes of subclinical inflammation in liver
[122]. Taken together, it seems that if there is a time in
women’s life where physical exercise is important, it is with
menopause.
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Objective. To summarize the recent studies on effect of conjugated linoleic acid (CLA) on hepatic steatosis and hepatic and adipose
lipid metabolism highlighting the potential regulatory mechanisms. Methods. Sixty-four published experiments were summarized
in which trans-10, cis-12 CLA was fed either alone or in combination with other CLA isomers to mice, rats, hamsters, and humans
were compared. Summary and Conclusions. Dietary trans-10, cis-12 CLA induces a severe hepatic steatosis in mice with a more
muted response in other species. Regardless of species, when hepatic steatosis was present, a concurrent decrease in body adiposity
was observed, suggesting that hepatic lipid accumulation is a result of uptake of mobilized fatty acids (FA) from adipose tissue
and the liver’s inability to sufficiently increase FA oxidation and export of synthesized triglycerides. The potential role of liver
FA composition, insulin secretion and sensitivity, adipokine, and inflammatory responses are discussed as potential mechanisms
behind CLA-induced hepatic steatosis.
1. Introduction
Obesity is a chronic metabolic nutritional disorder that
has increased at an alarming rate in the last 20 years [1].
In the US, 68% of the adults (age ≥ 20 years) and 18%
of children (2–19 years) are either obese or overweight
as per the National Health and Nutrition Examination
Survey [2, 3]. Incidence of obesity is associated with many
health complications such as hypertension, hyperlipidemia,
cardiovascular disease, type 2 diabetes [4], and a range of
lipid abnormalities, the most common being nonalcoholic
fatty liver disease (NAFLD) [4].
NAFLD is an important health concern due to its high
prevalence (∼20% of adult population) and its association
with insulin resistance and metabolic syndrome [5]. It is
characterized by hepatic lipid accumulation primarily in
the form of triglycerides (TG) [6]. Some of the potential
steps involved in the progression of NAFLD may involve
increased uptake of circulating fatty acids (FA) [7], increased
hepatic denovo lipogenesis (DNL) [8], reduced rate of
FA oxidation [9], or reduced FA secretion [10, 11]. When
NAFLD is associated with inflammation and fibrosis, it is
termed as nonalcoholic steatohepatitis (NASH), a serious
condition that could lead to liver cirrhosis, hepatic carci-
noma, and liver failure [12]. The pathogenesis of NAFLD
can be explained by “two hit” hypothesis suggesting steatosis
as the “first hit” which increases the vulnerability of liver to
various second hits like oxidative stress and inflammation
leading to NASH [13].
Although no specific guidelines exist for treatment of
NAFLD, recommendations are aimed at reducing body
weight due to its strong association with obesity and
metabolic syndrome [4]. In this regard, bioactive lipids/FA
as functional food may be important in modulating
metabolism and body weight. A specific group of polyun-
saturated FA collectively known as conjugated linoleic acid
(CLA) have been suggested to have an effect on regulating
energy metabolism [14] and is being used commercially
as a weight-loss supplement. CLA were recently granted
“Generally Recognized As Safe”, status in the United States
(GRN no. 232; http://www.cfsan.fda.gov/) for use as a dietary
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supplement. However, CLA effects are varied depending
on the type of CLA isomer, the animal’s physiological
condition, and the tissue type examined. In this paper, we
summarize the recent studies on effect of CLA on hepatic
lipid metabolism highlighting the potential regulatory mech-
anisms.
2. Conjugated Linoleic Acid
Conjugated linoleic acid refers to a group of dienoic deriva-
tives of linoleic acid with conjugated double bonds arranged
in different combinations of cis and trans configuration [15].
Currently, 16 naturally occurring CLA isomers have been
identified with different positional (7/9, 8/10, 9/11, 10/12,
and 11/13) and geometric (cis/cis, trans/trans, cis/trans, and
trans/cis) combinations [16, 17].
Sources of CLA include those naturally present in
dairy products and meat from ruminant animals or those
contained in industrially hydrogenated vegetable oils and
other synthetic products [14]. The CLA originating from
the ruminant products predominantly consist of cis-9, trans-
11 CLA (>80%), with a small amounts of trans-10, cis-12
CLA and other isomers [18]. The industrially synthesized
CLA and other commercial products intended for human
consumption typically consists of equal amounts of cis-9,
trans-11 CLA and trans-10, cis-12 CLA and other isomers
[19]. Of all the CLA isomers, cis-9, trans-11 CLA and trans-
10, cis-12 CLA have been the most widely studied due to their
biologically active properties [15].
3. Physiological Effects of CLA
A great deal of current interest in CLA is due to their bioac-
tive properties including anticarcinogenic [19], antiathero-
genic [20], immunity enhancing [21], and effects on body
composition [22]. Each CLA isomer has unique bioactive
properties, and hence, the biological effect from a mixture
of dietary CLA isomers, as is the case in most of the studies,
would be the combined effect of their distinct isomers
[15]. For example, cis-9, trans-11 CLA and trans-10, cis-12
CLA have additive effects on cancer [23] and immune cell
functions [24] but are antagonistic on insulin sensitivity.
While cis-9, trans-11 CLA improves insulin sensitivity, trans-
10, cis-12 CLA causes insulin resistance. Also, trans-10, cis-12
CLA is solely responsible for changes in body composition
and reducing adipose mass [25].
3.1. Body Weight and Lean Mass. CLA reduces body weight
and body fat mass and increases lean mass in different species
[22]. However, the response appears to vary depending on
species, physiological stage, and fat depot [22, 26]. Table 1
provides a summary of studies reviewed across species with
respect to body weight and adiposity, where the number
of experiments showing significant (P > 0.05) increases,
decreases, or no change and the mean response to dietary
trans-10, cis-12 CLA within those categories are reported.
The range of trans-10, cis-12 CLA addition in these studies
varied between 0.1 and 1 percent of the diet.
Trans-10, cis-12 CLA reduces body fat to a maximum
extent in mice (60% to 80%) [27, 28]. However, modest
and inconsistent effects are seen in rats [49, 82], hamsters
(9% to 58%) [54, 55], and pigs (6% to 25%) [83].
Similarly, variable responsiveness to CLA was observed for
epididymal, perirenal, and subcutaneous body fat depots
[55]. Inconsistent responses to trans-10, cis-12 CLA have
been reported in clinical trials with humans [84]. Some have
shown significant effects on body composition [63, 85],
while others have not [64, 65]. The differences in the
responses are attributed to differences in the dose levels,
age, and rate of adipose tissue TG turnover [14, 66, 84]. The
response to CLA isomers also depends on the physiological
state of the animal which is probably due to differences
in the preferential uptake of CLA by different tissues. For
example, trans-10, cis-12 CLA is preferentially taken up by
the mammary tissue during lactation leading to substantial
(∼45%) decrease in milk lipid synthesis [29].
3.2. Effects of CLA on Hepatic Lipid Metabolism. Liver plays
an important role in energy homeostasis, as it converts
excessive dietary glucose into FA which is exported as TG.
Liver is an important target for CLA effects irrespective of the
physiological condition. Of the different CLA isomers, trans-
10, cis-12 CLA causes increased lipid accumulation leading
to hepatic steatosis [30–32, 86]. However, the intensity of
lipid accumulation varies depending on the level of CLA
in the diet, duration of feeding, physiological condition,
and animal species (Table 1). The factors leading to hepatic
lipid accumulation are multifactorial involving increased
FA influx, increased FA synthesis, and altered FA oxidation
and TG secretion insufficient to prevent lipid accumulation
(Figure 1) [33]. These mechanisms are probably not
mutually exclusive and could act in a coordinated manner
to hasten the development and progression of fatty liver
[87].
3.2.1. Hepatic FA Synthesis. Under normal conditions, de
novo lipogenesis contributes minimally to the lipid pool
in the liver [88]. However, the lipid synthesis increases
to as much as 26% during steatotic conditions [89]. The
increase in hepatic lipid content due to CLA, specifically
trans-10, cis-12 CLA, is commonly associated with increased
hepatic lipogenesis [30]. In mice, CLA has been repeatedly
shown to increase the expression of sterol regulatory element-
binding protein-1c (SREBP-1c), key transcriptional regulator
in hepatic lipogenesis and its downstream genes acetyl CoA
carboxylase (ACC), fatty acid synthase (FASN), and stearoyl
CoA desaturase-1 (SCD1) [30, 34, 35] (Table 2). However,
in rats and hamsters, the responses are equivocal. The
increase in SREBP-1c expression in mice is attributed to
hyperinsulinemia (Figure 1) [30]. The decreased expression
of lipogenic (ACC1, ACC2, FASN, and SCD1) genes in
the absence of insulin in mice fed trans-10, cis-12 CLA
further supports this argument [33]. In addition to SREBP-
1c, insulin induces the expression of peroxisome proliferator-
activated receptor-γ (PPAR-γ) [90], which is in low abun-
dance under normal conditions [91]. PPAR-γ expression
is increased in steatotic liver (Figure 1) [30, 92], while its
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Table 1: Studies showing that trans-10, cis-12 CLA induced significant (P < 0.05) increases or decreases, or where there was no change (P >
0.05) in body, adipose, and liver weights and liver lipid concentration.
Species Change Body weight Adipose tissue Liver weight Liver lipids
Mice1
Increase — — 24 (92) 19 (515)
Decrease 21 (31)2 29 (666) — —
No change 16 — 2 2
Rats3
Increase — — — 1 (25)
Decrease — 1 (23) — 4 (19)
No change 11 3 8 4
Hamsters4
Increase — — 8 (20) —
Decrease 2 (14) 11 (20) — 3 (37)
No change 11 2 2 5
Humans5
Increase — — — —
Decrease 2 6 — —
No change 11 13 — —
1
Studies used: [22, 25, 27–48].
2Number of observations (mean percent change).
3Studies used: [49–53].
4Studies used: [54–62].
5Studies used: [63–81].
Figure 1: Current concepts in the pathways of trans-10, cis-12 CLA-induced hepatic steatosis. (1) Adipose tissue lipodystrophy caused by
increased proinflammatory cytokines and reduced adipokines leading to higher circulatory levels of free FA (FFA). (2) Hyperinsulinemia
induced by systemic insulin resistance. (3) Alterations in hepatic lipid metabolism leading to hepatic steatosis. (4) Alterations in hepatic
FA composition. SREBP-1c, Sterol regulatory element-binding protein-1c; PPAR-γ, peroxisome proliferator activated receptor-γ; TNF-α, tumor
necrosis factor-α; IL-6, interleukin-6; IL-8, interleukin-8; PEPCK, phosphoenol pyruvate carboxykinase; G6P, glucose 6-phosphatase; ChREBP,
carbohydrate response element-binding protein; PPAR-α, peroxisome proliferator-activated receptor-α; LC-PUFA, long chain polyunsaturated
FA.
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ablation ameliorates the condition in mice [93]. Insulin resis-
tance in response to trans-10, cis-12 CLA could upregulate
genes of glucogenic pathway (e.g., PEPCK, G6P) leading
to hyperglycemia (Figure 1) [94]. In turn, elevated blood
glucose concentrations could upregulate hepatic lipogene-
sis through carbohydrate response element binding protein
(ChREBP), a transcriptional regulator modulated by glucose
(Figure 1). The targeted deletion of ChREBP in the liver
improves the steatotic conditions in ob/ob mice [94]. How-
ever, the role of ChREBP in CLA-induced hepatic steatosis is
not known. Although hyperinsulinemia triggers the hepatic
lipogenesis, CLA-induced hepatic steatosis in the absence
of insulin suggests the involvement of other regulatory
mechanisms affecting hepatic lipid accumulation [33].
3.2.2. Hepatic FA Uptake and TG Secretion. In mouse
experiments, dietary trans-10, cis-12 CLA was associated
with upregulation of genes associated with FA uptake and
TG secretion (FAT/CD36; Table 2). During hepatic steatosis
about 59% of hepatic TG is derived from free FA released
from the adipose tissue and 15% is derived from dietary fat
[89]. FA transporters, (FATP5, FAT/CD36, FABP-1, FABP-4,
and FABP-5) regulate the FA uptake by hepatocytes. While
the overexpression of these proteins promotes steatosis,
functional deletion ameliorates the condition [98–100]. As
CLA are natural ligands and activators of PPAR-γ [101] the
upregulation of FAT/CD36 by trans-10, cis-12 CLA [32, 33,
102] could be through PPAR-γ leading to increased hepatic
FA uptake. In addition to FAT/CD36, we have observed
modest increases in the expression of FABP-1 (1.39 fold) and
FABP-2 (1.7 fold) in liver of lactating mice fed trans-10, cis-
12 CLA (Kadegowda, A. K. G., Erdman, R. A., and Loor, J. J.,
unpublished results).
Besides enhanced FA uptake and lipogenesis, alteration
in very low-density lipoprotein (VLDL) secretion rates could
also result in liver fat accumulation [103]. The VLDL
production and secretion is increased in response to elevated
lipid concentrations. However, impaired or insufficient fat
export via VLDL predisposes animal to hepatic steatosis
[10]. Trans-10, cis-12 CLA reduced TG secretion leading to
higher lipid accumulation in HepG2 cells due to reduced
apolipoprotein B synthesis [104]. Conversely, lipoprotein
clearance was not affected in mice fed CLA [31, 102]. The
TG export was increased with higher rate of VLDL secretion;
however, it was insufficient to eliminate increased FA flux
entering the liver leading to hepatic steatosis [31].
3.2.3. Hepatic FA Oxidation. Hepatic FA oxidation encom-
passes β-oxidation in mitochondria and peroxisomes and ω-
oxidation in the microsomes [105]. The FA < C8 to C20 are
catabolized through the mitochondrial β-oxidation pathway,
while FA > C20 are initially catabolized in the peroxisomes
to shorter FA which are then shuttled to mitochondria
for further oxidation [32]. Previous studies have reported
variable responses in hepatic FA oxidation with trans-10,
cis-12 CLA. Most of the studies have shown increased FA
oxidation [27, 34, 36, 56, 106], while some have reported
reduced [32] or unaltered FA oxidation [22] with CLA.
Carnitine palmitoyltransferase-1 (CPT1) is the rate lim-
iting enzyme for mitochondrial β-oxidation pathway, as it
regulates the transport of fatty acyl CoA into mitochondria.
When measured in mice, CPT1 gene expression was consis-
tently increased by CLA (Table 2) which might be mediated
through transcriptional regulator PPAR-α as it regulates
the key enzymes (e.g., CPT1, CPT2, and ACO) involved in
hepatic FA oxidation [50].
Despite increased FA oxidation hepatic steatosis was
consistently observed in mice (Tables 1 and 2). Since studies
showing increased FA oxidation were also associated with
increased hepatic lipogenesis, it is possible that that the
rates of hepatic lipogenesis far exceed the rates of FA
oxidation resulting in increased lipid accumulation. Along
with increased lipogenesis the level of malonyl CoA, a
product of ACC, was also increased that allosterically inhibits
CPT1 enzyme activity [36]. Thus, despite higher expression
of FA oxidation genes, it is possible that FA combustion
might be depressed in vivo leading to steatosis.
Some studies have shown CLA induced downregulation
of genes related to mitochondrial β-oxidation (CPT1), and ω
oxidation (cyt P450 and FMO3) [32]. We have also observed
decreased expression of CPT1, ACOX1, and FMO3 without
any changes in hepatic lipogenic genes of lactating mice
fed trans-10, cis-12 CLA (Kadegowda, A. K. G., Erdman,
R. A., and Loor, J. J., unpublished results). The variable
responses among different studies can be attributed to the
level and type of fat used in the experimental diet along
with the physiological conditions of animal used in the
experiment.
3.2.4. Effect of CLA on Hepatic FA Composition. Trans-
10, cis-12 CLA-induced hepatic steatosis is characterized
by changes in hepatic FA composition [29, 37, 107–111]
similar to those induced during NAFLD [112]. The hepatic
FA composition in steatotic liver determines the extent of
susceptibility of liver injury [113]. The steatotic liver FA pro-
file is characterized by substantial reductions in long chain
polyunsaturated FA (LC-PUFA) concentrations; specifically
that of arachidonic acid (C20:4n-6). While linoleic (18:2n-
6) and α-linolenic acid (18:3n-3) are unaltered, the con-
centrations of eicosapentaenoic acid (EPA, C20:5n-3) and
docosahexaenoic acid (DHA, C22:6n-3) are decreased. The
desaturation and elongation of linoleic and α-linolenic acid
by desaturases (Δ5-desaturase, Δ6-desaturase) and elongases
(ELOVL-2, ELOVL-3) are involved in synthesis of LC-PUFA.
Trans-10, cis-12 CLA inhibits both Δ5- and Δ6-desaturase in
HepG2 cells [114]. A recent tracer study with [U-13C] linoleic
acid showed significant reduction in n-6 PUFA synthesis
by inhibition of elongation and desaturation in the liver
homogenates of neonatal pigs [115]. A decrease in arachi-
donic acid synthesis would alter eicosanoid metabolism and
potentially reduce the synthesis of prostaglandin E2 (PGE2)
[116] which is known to have protective effects on liver [117].
Typical NAFLD is also characterized by increased n-
6 : n-3 LC-PUFA ratio which favors lipid synthesis over lipid
oxidation and secretion leading to hepatic lipid accumu-
lation [118]. Trans-10, cis-12 CLA reduces the n-3 PUFA
in liver [38, 109] in addition to arachidonic acid. The
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Table 2: Studies showing that trans-10, cis-12 CLA induced significant (P < 0.05) increases (↑), decreases (↓), or no change (↔) (P > 0.05)
in hepatic gene expression and circulating levels of insulin, adipokines, and TNF-α. Genes are classified based on their ascribed function.
Mice1 Rats2 Hamsters3
↑ ↓ ↔ ↑ ↓ ↔ ↑ ↓ ↔
Lipogenesis
ACC 5 (126)4 — 1 — — — 1 (99) — 1
FASN 7 (243) — 1 — 1 (50) 2 — — 2
SCD1 2 (150) — 3 — 1 (80) — — — —
SREBP-1c 3 (53) — 2 — 1 (40) 4 — — 3
PPAR-γ 2 (200) — — — — 2 — — —
ME 5 (205) — — — — — — — —
FA uptake, secretion, and oxidation
CPT1 4 (107) 1 (59) 1 — — — — — 2
ACO 5 (117) — 1 2 (130) — 4 — — 2
PPAR-α — 1 (53) — 1 (125) — — — — 3
FAT/CD36 3 (533) — — — — — — — —
LPL — — 1 — — — — — 1
Insulin, adipokines, and TNFα
Insulin 12 (2492) 1 (29) 3 — — 3 — — 1
Adiponectin — 6 (77) 5 — — — — — —
Leptin — 10 (71) — — — 1 — — —
TNF-α — 4 (32) 1 1 (44) 2 — — —
↑, ↓,↔; increase, decrease or no changes respectively.
1Studies used: [27, 29–35, 45, 95, 96].
2Studies used: [49–52, 97].
3Studies used: [54, 56, 59, 61].
4Number of observations (mean percent change).
ACC: acetyl CoA carboxylase, FASN: fatty acid synthase, SCD1: stearoyl CoA desaturase-1, SREBP-1c: sterol regulatory element-binding protein-1c, PPAR-
γ: peroxisome proliferator activated receptor-γ, ME: malic enzyme, CPT1: carnitine palmitoyl transferase 1, ACO: acyl-CoA oxidase, PPARα: peroxisomal
proliferator activated receptor α; FAT/CD36: fatty acid translocase, LPL: lipoprotein lipase.
n-3 PUFA downregulate SREBP-1c and upregulate PPAR-
α, which regulates lipid oxidation (CPT1, ACOX1) and
secretion (ApoB100). A decrease in hepatic n-3 PUFA would
not only reduce lipid oxidation but increase lipogenesis
leading to hepatic steatosis [118]. Although the trans-10,
cis-12 CLA-induced responses in FA oxidation are variable
in mice, consistently increased lipogenesis (Table 2) suggests
a potential role for n-3 PUFA. On the contrary, CLA
feeding increased n-3 PUFA content and decreased n-6 PUFA
in the rats [119, 120] which could probably explain the
differences in CLA effects between the two species. Although
the exact mechanism of CLA action has not been elucidated,
Banni et al. [121] has suggested that the metabolites of
CLA, conjugated dienes (CD)18:3, CD20:3, CD20:4, could
compete with other PUFA at the level of formation and
metabolism in liver and affect LC-PUFA synthesis.
3.3. CLA and SCD in Hepatic Lipid Metabolism. In the adi-
pose, there are some similarities between the effects of trans-
10, cis-12 CLA and the inhibition of SCD1. For example,
reduced adiposity is observed with both dietary trans-10,
cis-12 CLA and SCD1 inhibition and one could speculate
that the effects of trans-10, cis-12 CLA are mediated through
SCD1 as trans-10, cis-12 CLA decreases SCD1 in adipose
[122]. However, a study with SCD1−/− mice showed that the
antiobesity effects of trans-10, cis-12 CLA were independent
of SCD1 gene expression and enzyme activity [123].
Unlike adipose, the effects of trans-10, cis-12 CLA
are varied in liver (Table 2). While trans-10, cis-12 CLA
decreased hepatic SCD activity in vitro [124], in vivo studies
report increased hepatic SCD1 gene expression [32, 95]. In
contrast to trans-10, cis-12 CLA effects in mice, SCD1−/−
mice showed increased insulin sensitivity, reduced hepatic
lipogenic genes, upregulated lipid oxidizing genes, increased
hepatic saturated FA and unchanged hepatic n-3 and n-6
PUFA [125]. SCD1−/− mice fed trans-10, cis-12 CLA showed
reduced hepatic accumulation compared to wild type [123]
confirming that reduced SCD1 expression decreases hepatic
lipid accumulation [126]. Liver specific SCD1 knock out
decreased expression of SREBP1 and ChREBP and their
target genes there by reducing hepatic lipogenesis [127].
In contrast, short-term inhibition of tissue specific hepatic
SCD increased hepatic TG content and enhanced insulin
signaling, [128] but the long-term inhibition decreased
hepatic steatosis [129]. The differences in responses observed
in liver specific knockout versus complete SCD knockout
mice suggests that hepatic lipid metabolism is being affected
by lipid metabolism in nonhepatic tissues [130].
As trans-10, cis-12 CLA effects in mice are mostly
associated with insulin resistance; increased hepatic SCD1
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expression is probably due to increased SREBP-1c expres-
sion. Hepatic steatosis due to trans-10, cis-12 CLA is also
seen in the absence of insulin and is associated with
reduced expression of SCD1 and other lipogenic genes
[33]. These results indicate that the disturbances in hepatic
lipid metabolism caused by dietary trans-10, cis-12 CLA are
mediated by multiple mechanisms [131] rather than through
changes in SCD1 alone.
3.4. Role of Adipose during CLA-Induced Hepatic Steatosis.
The effect of CLA on adipose lipid metabolism is well
documented [14]. Of all the CLA isomers, trans-10, cis-12
CLA is the most potent to induce changes in adipose [25].
The changes may be caused by reduced lipid content, size,
and number of adipocytes. Trans-10, cis-12 CLA reduces
lipogenesis by decreasing expression of SREBP-1c and PPAR-
γ and their downstream genes, ACC, FASN, and SCD1,
reduces glucose and FA uptake by reducing GLUT4 and
LPL expression, increases FA oxidation by increasing CPT1
and UCP2 expression and reduces adipocyte proliferation
and differentiation by reducing PPAR-γ and its downstream
genes [131]. Furthermore, CLA affects various adipocyte
secreted-adipokines (e.g., leptin, adiponectin, and resistin)
and cytokines (e.g., TNFα and IL6), which are involved in
wide range of physiological activities [14]. Trans-10, cis-12
CLA increases the mRNA expression of cytokines, TNFα and
IL6 in adipose tissue [131]. However, the circulating cytokine
levels are reduced in response to trans-10, cis-12 CLA
(Table 2). The increased cytokine expression in adipose tissue
is known to reduce the activity of PPAR-γ [132], and thereby
affect its downstream cellular functions. Also, TNFα and IL6
inhibit the activation of insulin receptor substrate-1 (IRS-
1) through induction of suppressors of cytokine signaling
(SOCS3) disrupting insulin action [133]. The expressions of
TNFα and adiponectin, an adipokine associated with insulin
sensitivity, are inversely related [134]. The adipose tissue
depletion would reduce the level of adiponectin and when
coupled with increased TNFα would lead to severe insulin
resistance. The subsequent pancreatic β cell hyperplasia, as
a compensatory mechanism to insulin resistance, leads to
hyperinsulinemia which promotes lipid accretion in the liver
leading to hepatic steatosis [39].
In mice, trans-10, cis-12 CLA causes severe lipodystrophy
reducing the levels of leptin and adiponectin (Table 2), which
leads to hepatic steatosis (Table 1, Figure 1). Re-establishing
the levels of leptin or adiponectin either through external
supplementation (in case of leptin) or induction using
rosiglitazone (ROSI) (in case of adiponectin) attenuated
hepatic steatotic condition and normalized the insulin levels
in CLA-fed mice [135, 136]. Similar results are seen in
studies where prevention of lipodystrophy prevented lipid
accumulation in the liver [135]. Serum insulin levels are
directly correlated with liver TG, while serum adiponectin
levels are inversely related [35]. Adipokines could improve
the condition of the liver by lowering the insulin levels.
However, hepatic steatosis is seen in mice even at low
insulin levels [33], suggesting that different mechanisms
could regulate the induction of hepatic steatosis depending
on the animal’s physiological condition. The intensity of
hepatic steatosis could be directly related to the relative
amounts of adipose tissue. CLA-induced hyperinsulinemia
and hepatic steatosis are observed only if there are corre-
sponding decreases in the adipose tissue mass [40, 135].
Stout et al. [137], reported increases in diacylglycerol (DAG)
concentration and membrane associated protein kinase C
(PKC) during trans-10, cis-12 CLA-induced hepatic steato-
sis. Increased PKC would affect insulin signaling leading
to insulin resistance, hyperinsulinemia, and hyperglycemia
[137].
3.5. CLA and Inflammatory Responses. In addition to its
effects on lipid metabolism, trans-10, cis-12 CLA also induces
an inflammatory response in adipose tissue [131, 138].
Trans-10, cis-12 CLA activates integrated stress response
leading to activation of NF-kB pathway, induction of
inflammatory cytokines, TNFα, IL6, and IL8 [41, 138, 139],
and macrophage infiltration [35]. However, the level of
circulating cytokines, TNFα and IL6, were decreased in
response to trans-10, cis-12 CLA [42, 43]. In contrast to
the adipose, the effects of CLA on hepatic inflammatory
responses are not well defined. Trans-10, cis-12 CLA did
not affect expression markers of macrophage infiltration in
mice liver such as TNFα or F4/80 and CD68 during hepatic
steatosis [35]. However, trans-10, cis-12 CLA increased
expression of markers of hepatic inflammation in hamsters
without inducing hepatic steatosis [57]. The authors in [57]
attributed this to an increased capacity of the liver for higher
FA oxidation leading to inflammation and oxidant stress
defense pathway in the hamsters.
4. Prevention or Amelioration of CLA-Induced
Hepatic Steatosis
Several studies have examined either the prevention or ame-
lioration of trans-10, cis-12 CLA-induced hepatic steatosis
(Table 3) by normalizing serum adipokine levels, altering
hepatic PUFA composition or both. External supplementa-
tion of recombinant murine leptin ameliorate CLA-induced
hepatic steatosis and hyperinsulinemia by decreasing hepatic
lipogenesis and increasing insulin sensitivity respectively
[40, 136]. Serum adiponectin levels were not restored (and
remained low) even after leptin supplementation, prompting
the authors in [136] to claim that leptin alone could amelio-
rate CLA induced steatosis. Conversely, trans-10, cis-12 CLA-
caused hyperinsulinemia associated with lipid steatosis in
Ob/Ob mouse which lack functional leptin [143] suggests the
involvement of other factors. Increasing adiponectin levels by
supplementation of ROSI attenuates liver fat accumulation in
Ob/Ob mouse [49]. ROSI prevented lipodystrophy, decreased
hepatic lipogenesis and subsequently liver TG content [35].
The insulin sensitizing action of leptin and adiponectin
normalizes insulin levels which further helps in preventing
CLA-induced steatosis [40, 141].
Dietary FA or oil supplements with higher n-3 and
n-6 PUFA are able to ameliorate liver steatosis when
supplemented along with CLA. Supplementing arachidonic
acid [140] or its precursor γ-linolenic acid (18:3n-6) [44]
decreased induction of hepatic steatosis and increased liver
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Table 3: Summary of literature studies on amelioration of CLA induced hepatic steatosis.
% Added dietary CLA
Reference
No. per
treatment
Study days CLA Mix
trans-10
cis-12
Treatment
Treatment dose,
%1
Observations
[136] 3 to 6 28 2.0 0.95 Leptin 5 μg/d
↓Hepatic steatosis, ↑ insulin
sensitivity,
[40] 5 to 14 30 1.0 0.72 Leptin 5 μg/d
↑ insulin sensitivity, amelio-
rated hepatic steatosis
[49] 5 28 1.5 0.60 Rosiglitazone 10mg/kg BW
↑ Insulin sensitivity, pre-
vented depletion of epi-
didymal adipose tissue
[35] 10 42 2.0 1.00 Rosiglitazone 10mg/kg BW
↓ Hepatic TG content, ↓
hepatic lipogenesis,↑ serum
leptin and adiponectin, pre-
vents lipodystrophy
[140] 7 28 3.0 0.98
Arachidonic
acid
1, 2
↓ Induction of hepatic
steatosis, ↑ liver PGE2, ↑
epididymal adipose
[44] 7 28 — 1.20
γ-Linolenic
acid
5 ↓Hepatic steatosis, ↑ PGE2
[38] 10 56 — 0.50
Flax seed oil
(α- Linolenic
acid)
0.39
↓ Steatosis, ↑ n-3 and n-6
PUFA in liver
[27] 7 to 8 22 1.0 0.50 Fish oil 1.5, 3, 6
↑ Leptin and Adiponectin, ↓
Insulin, ↓ TG in liver, ↑ fat
pad
[141] 10 105 1.0 0.50 Pine oil 7.5
Serum insulin levels stabi-
lized over 3 weeks
[135] 5 to 6 100 1.0 0.35
34% dietary
fat
Normal plasma insulin lev-
els, ↑ liver weight
[45] 6 28 2.0 0.74 DHA 0.5
↓ Fatty liver, ↓ FA syn-
thesis, plasma leptin, and
adiponectin unaffected
[142] 10 56 — 0.50 DHA, EPA 0.5, 0.5
Prevented hepatic steatosis,
partially restored plasma
leptin, only DHA restored
plasma adiponectin
1
Percentage in the diet except wherever noted.
PGE2 levels. Hepatic steatosis is characterized by significant
reduction in the levels of arachidonic acid in liver. Arachi-
donic acid supplementation would not only normalize the
level of respective FA but would also increase the levels of
hepatic PGE2 [44, 140]. Both arachidonic acid and PGE2
would further reduce hepatic lipogenesis by decreasing FASN
and S14 gene expression [140, 144] thereby preventing
hepatic steatosis.
The importance of n-3 PUFA concentrations on hepatic
lipid metabolism was explained in the earlier section. Trans-
10, cis-12 CLA decreases liver n-3 PUFA concentrations
which affect hepatic lipid metabolism. Dietary supplements
enriched in n-3 PUFA along with CLA diet increased the
content of n-3 and n-6 PUFA in liver [38]. Fish oil, a source of
PUFA has been shown to ameliorate CLA-induced steatosis
by increasing leptin and adiponectin levels and decreasing
plasma insulin [27]. Pinolenic oil, a source of Pinolenic
acid was able to stabilize insulin levels when fed with CLA
[141]. Similarly, flaxseed oil, a source of α-linolenic acid was
able to increase n-3 and n-6 PUFA in liver. Supplementing
EPA and DHA prevents lipid accumulation when fed with
trans-10, cis-12 CLA [45, 142]. This effect was independent
of their effects on stabilizing insulin sensitivity. Both EPA
and DHA have modest effects in restoring plasma leptin
levels, while DHA alone can restore plasma adiponectin
levels to some extent [142]. The effects of DHA in preventing
hepatic steatosis were mediated through decreasing hepatic
lipogenesis [45].
5. Role of cis-9, trans-11 CLA in
Hepatic Metabolism
Of the 16 naturally occurring CLA isomers, trans-10, cis-12
CLA and cis-9, trans-11 CLA have been the most extensively
studied with respect to their bioactive properties. Most
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of the animal studies have used a CLA mixture having
trans-10, cis-12 CLA and cis-9, trans-11 CLA in 1 : 1 ratio
to study the effect of CLA on liver metabolism. Studies
using purified CLA isomer have delineated the differences
between the two isomers. While trans-10, cis-12 CLA leads
to decreased adipose tissue leading to insulin resistance,
hyperinsulinemia, and hepatic steatosis, cis-9, trans-11 CLA
shows only modest effects in mice [30–32, 86] and hamsters
[56, 58]. Similarly, the effects of CLA on SCD1 gene and
protein expression are isomer specific [145]. Contrary to
trans-10, cis-12 CLA, cis-9, trans-11 CLA has no effect on
SCD1 gene expression either in vitro [124] or in vivo [95].
A few studies have reported beneficial effects of cis-9,
trans-11 CLA. For example, cis-9, trans-11 CLA did not alter
liver lipid content but reduced 18:1n-9 and 18:1n-7 and
increased 18:2n-6 in TG in contrast to trans-10, cis-12 CLA
[108]. In addition, cis-9, trans-11 CLA promotes insulin
sensitivity [42, 43] by reducing adipose inflammation
[41, 132]. Furthermore, it enhances hepatic mitochondrial
function and protects against oxidative stress by increasing
activities of mitochondrial antioxidant enzymes [146]. The
anti-inflammatory role of cis-9, trans-11 CLA is related
to the induction of anti-inflammatory heat shock protein
(HSP) 70 kDa and decreased expression of proinflammatory
macrophage migration inhibitory factor [147].
6. Conclusions
Hepatic steatosis induced by trans-10, cis-12 CLA is
associated with lipodystrophy in addition to insulin
resistance, hyperinsulinemia, and hyperglycemia in mice
(Figure 1). These effects are largely attributed to decreased
adipokine (leptin and adiponectin) secretion. Dietary inter-
ventions preventing lipodystrophy or normalizing leptin and
adiponectin levels prevents or ameliorates hepatic steatosis in
mice, suggesting that adipose tissue responsiveness to trans-
10, cis-12 CLA could be the main contributing factor. The
moderate responsiveness of adipose tissue to trans-10, cis-
12 CLA observed in hamsters and rats results in lower (or
absence of) hepatic TG accumulation when compared with
mice (Table 1) explains species specific responses.
Hepatic steatosis, due to increased lipid accumulation, is
multifactorial and is largely attributed to increased rates of
lipid synthesis along with lipid uptake, and it far exceeds the
rates of FA oxidation and VLDL secretion. In addition, trans-
10, cis-12 CLA-induced hepatic steatosis is characterized by
reduction of n-6 PUFA (especially C20:4n-6) and n-3 PUFA
(Figure 1). Changes in hepatic FA composition could play an
important role in progression of hepatic steatosis, as normal-
izing the levels of n-6 PUFA or n-3 PUFA by dietary supple-
mentation prevents or ameliorates hepatic lipid accumula-
tion. Further studies are needed to understand the molecular
mechanisms and the interrelationship between trans-10, cis-
12 CLA-induced hepatic steatosis and altered hepatic PUFA
content. We are still lacking mechanistic details showing
relationship between adipokine levels, insulin resistance, and
hepatic FA composition in context of hepatic steatosis, and it
needs to be addressed in the future experiments.
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The present study was designed to investigate the impact of exercise training on lipogenic gene expression in liver and lipid
partitioning following the ingestion of a high fructose load. Female rats were exercise-trained for 8wk or kept sedentary before
being submitted to a fasting/refeeding protocol. Rats were further subdivided as follow: rats were fasted for 24 h, refed a standard
diet for 24 h, starved for another 24 h, and refed with a standard or a high-fructose diet 24 h before sacrifice. Fructose refeeding was
associated with an increase in hepatic lipid content, endocannabinoid receptor 1, sterol regulatory element-binding protein1c, and
stearoyl-CoA desaturase1 gene expression in both Sed and TR rats. However, desaturation indexes measured in liver (C16 : 1/C16 : 0
and C18 : 1/C18 : 0) and plasma (C18 : 1/C18 : 0) were higher (P < 0.01) in TR than in Sed rats following fructose refeeding. It is
concluded that exercise training does not significantly affect fat accumulation and the molecular expression of genes involved in
lipogenesis after fasting and fructose refeeding but does modify the partitioning of lipids so as to provide more unsaturated fatty
acids in liver without affecting liver fat content.
1. Introduction
The recent interest in liver fat metabolism has been spurred
by the finding that obesity in Western societies results in
an accumulation of hepatic lipids that, in turn, is associated
with the deterioration of insulin signalling [1–3]. The clinical
relevance of lipid handling by the liver has been enlightened
by the finding that, when rats are starved and subsequently
refed, liver lipids rapidly accumulate, especially when fed
carbohydrates [4]. This phenomenon is closely associated
to repeated bouts of weight loss and regain, also known as
weight cycling or “yo-yo” dieting [5]. At the gene expression
level, a food deprivation/refeeding regimen using high-
carbohydrate diets results in the upregulation of several hep-
atic lipogenic enzymes such as fatty acid synthetase (FAS) [6–
8] and stearoyl-CoA desaturase1 (SCD1) [9, 10]. Although
no study has reported the effects of fasting/refeeding high-
carbohydrate diets on endocannabinoid receptor 1 and 2
(CB1-2), experimental evidence suggests that hepatic CB
receptors contribute to the development of diet-induced
hepatic steatosis through the induction of the lipogenic tran-
scription factor SREBP1c and its target enzymes (i.e., FAS)
[11, 12]. Simple sugars, abundantly found in fruit drinks,
sports drinks, and soda, seem to strongly induce obesity and
hepatic steatosis in comparison to complex carbohydrates
[13–15]. Among simple sugars, fructose is the most potently
lipogenic inducer that can increase lipogenesis through acti-
vation of SREBP1c dependent and independent mechanisms
[14, 16].
On the other hand, chronic exercise training affects liver
fat metabolism by reducing the accumulation of liver lipids
in high-fat fed animals and in humans [17–19]. Although
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these training adaptations would be compatible with a
decrease in long-term fat accumulation, it may represent
a disadvantage in an acute situation, such as food depri-
vation/refeeding a high-fructose diet, in which an increase
in hepatic lipogenic activity is necessary to rapidly and
adequately buffer the large arrival of substrates. Investigating
the role of training on the short-term management of
fructose by the liver, in a food-deprived/refed situation, has
been limited to the impact of an acute bout of exercise
that inhibits key hepatic lipogenic enzymes [7, 8]. Proper
handling of substrates by the liver may have subsequent
implications on plasma TAG clearance and fat storage,
which, in turn, has implications on inflammation and
atherosclerosis development [20]. By contrast to training,
it has been reported that physical inactivity, known to
deteriorate muscle insulin signalling [21], impacts the par-
titioning of saturated versus unsaturated fatty acids toward
storage, resulting in a preferential accumulation of palmitate
(C16 : 0) in muscle fat [22]. Physical inactivity also decreases
dietary palmitate (C16 : 0) but not oleate (C18 : 1) oxidation,
suggesting that the desaturation status of fatty acids is an
important factor in determining their fate.
The first purpose of the present study was, therefore, to
determine the effects of an 8-week-exercise training program
on HFr refeeding-induced lipogenesis by measuring the
expression of the lipogenic genes CB1, CB2, SREBP1c, SCD1,
and fatty acid amide hydrolase (FAAH), an endocannabinoid
degrading enzyme known to be involved in liver lipid
infiltration [11, 23, 24]. It is postulated that under the present
fasting/refeeding protocol, TR would be associated with an
increased hepatic lipogenic activity. The second objective was
to examine the effects of TR on lipid partitioning by mea-
suring fatty acid desaturation index of SCD1 activity in liver
and plasma expressed under the ratio of monounsaturated
to saturated fatty acids (C16 : 1/C16 : 0 and C18 : 1/C18 : 0) in
the context of high-fructose refeeding.
2. Materials and Methods
2.1. Animal Care. Female Sprague-Dawley rats (Charles
River, St-Constant, PQ, Canada), weighing 180–200 g (6
weeks of age), upon their arrival were housed individually
and had ad libitum access to food and tap water (n = 40).
Female rats were used in the present study to avoid the
decrease in food intake and body weight that was observed
in exercise-trained male rats [25, 26]. Their environment was
controlled in terms of light (12 : 12-h light-dark cycle starting
at 6:00 AM), humidity, and room temperature (20–23◦C).
This experiment was conducted according to the directives
of the Canadian Council on Animal Care after the University
of Montreal (Montreal, PQ, Canada) approval.
2.2. Exercise Training Protocol. Four days after their arrival,
all animals were randomly assigned to a sedentary (Sed) or
an exercise-trained group (TR). Exercise training consisted
of continuous running on a motor-driven rodent treadmill
(Quinton Instruments, Seattle, WA) 5 times/week for 8
weeks. Exercise intensity was progressively increased from
15min/day at 15m/min, 0% slope, up to 60min/day at
Table 1: Composition of the diets.
Ingredients Amount (Kcal %)
SD HFr∗
Fat 12. 5% 13%
Saturated 30 % 42 %
Unsaturated 70 % 58 %
Carbohydrate 63.2 % 66.8 %
Protein 24.3 % 20.2 %
Gross energy Kcal/g 3.5 3.6
SD: standard diet, HFr: high-fructose diet.
Standard laboratory rat chow (5075, Charles River). The main carbohy-
drate is starch (65 % of total carbohydrates).
∗High-fructose diet (TD 89247, Harlan Teklad). The main carbohydrate is
fructose (99.23 % of total carbohydrates).
26m/min, 10% slope, for the last 4 weeks of the program.
Based on previous measurements of oxygen consumption
during a progressive exercise test in rats, it was estimated
that exercise intensity during the last 4 weeks of the training
program occurred at∼65% of maximal oxygen consumption
[27]. At the end of this 8-week period, animals were
sacrificed 36 to 48 h after the last exercise session.
2.3. Dietary Treatment Protocol. During the first complete
7 weeks, Sed and TR animals had free access to a standard
diet (SD; 12.5% lipid, 63.2% carbohydrate, and 24.3%
protein; kcal) consisting of usual pellet rat chow (Agribrands
Canada, Woodstock, ON). Toward the end of the 8th week
that corresponded to 4 days prior to sacrifice, animals
were submitted to two fasting and refeeding cycles [10]. Sed
and TR animals fasted for 24 h, refed the SD diet for 24 h,
starved for another 24 h, and then refed either the SD or an
isoenergetic high-fructose (HFr) diet for 24 h. The HFr diet
consisted of 13% lipid, 66.8% carbohydrate mainly fructose,
and 20.2% protein (kcal). Details of the diets are presented
in Table 1. Body weight and food intake were monitored 3
times/week in all rats during the first 7 weeks and every day
during the fasting/refeeding stage.
2.4. Blood and Tissue Samplings. All animals were sacrificed
between 09:00 and 11:00 AM. Food was removed from
the animals’ cage at least 3 h before sacrifice. After com-
plete anaesthesia (pentobarbital sodium, 50mg/kg ip), the
abdominal cavity was rapidly opened along the median line
of the abdomen. Blood was rapidly (<45 s) drawn from the
abdominal vena cava (∼4mL) into syringes pretreated with
EDTA (15%). Thereafter, blood was centrifuged (3,000 rpm
for 10min, 4◦C). The liver median lobe was freeze-clamped
and used for mRNA, Western blot, and lipid analysis.
The mesenteric (Mes), urogenital (Ug), and retroperitoneal
(Rp) fat deposits were excised and weighed in that order.
Mesenteric fat pad consisted of adipose tissue surrounding
the gastrointestinal tract from the gastrooesophageal sphinc-
ter to the end of the rectum with special care taken in
distinguishing and removing pancreatic cells. Urogenital fat
pad included adipose tissue surrounding the kidneys, ureters,
and bladder in addition to the ovaries, oviducts, and uterus.
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Table 2: Real-time PCR primer sequences.
Gene Sense (5′-3′) Antisense (5′-3′) Accession no.
CB1 AAGGACCTGAGACATGCTTTCCGA TCGCGATCTTAACGGTGCTCTTGA X55812
CB2 GGGGTGGACTTGTTGTCCTA ACATGTTGGTGTGCTTTCCA NM 020543
FAAH ACGATGCCCAGATGGAACTCTACA GCATGAACCTCAGACACAGCTCTT U72497
SCD1 CCTTAACCCTGAGATCCCGTAGA AGCCCATAAAAGATTTCTGCAAA J02585
SREBP1c ACGACGGAGCCATGGATTGCAC CCGGAAGGCAGGCTTGAGTACC L16995
β-actin CATGAAGATCAAGATCATTGCTCCT CTGCTTGCTGATCCACATCTG V01217
CB1: endocannabinoid receptor1.
CB2: endocannabinoid receptor2.
FAAH: fatty acid amide hydrolase.
SCD1: stearoyl-CoA desaturase1.
SREBP1c: sterol regulatory element-binding protein1c.
Retroperitoneal fat pad was taken from the fat deposit behind
each kidney along the lumbar muscles. Skeletal muscles
(plantaris, soleus, medial, and lateral gastrocnemius) of the
right limb were removed and weighed thereafter. All tissue
samples were immediately frozen in liquid nitrogen after
being weighed. All plasma and tissue samples were stored at
−80◦C until analyses.
2.5. Analytical Procedures
2.5.1. Quantitative Real-Time PCR. Total RNA was extracted
from frozen liver tissue with the use of either TRIzol (Invitro-
gen Canada Inc, Burlington, ON) or Purelink RNA mini Kit
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocol. RNA was treated with DNase (Invitrogen) in order
to avoid genomic contamination. Treated RNA was reverse-
transcribed into cDNA using either the random hexamer
primers (Invitrogen) and reverse transcriptase (Invitrogen),
or the transcriptor first-strand cDNA synthesis kit Roche
Diagnostics, Mannheim, Germany. Subsequently, we added
2 μL cDNA to 18 μL of a reaction mixture containing
SYBR Green Supermix from Bio-Rad Laboratories Inc. for
SCD1 and SREBP1c and from Roche Diagnostics Manheim,
Germany, for CB1, CB2, and FAAH. As for the previous
steps, polymerase chain reaction (PCR) was performed in
two different PCR machines. An iCycler IQ Real-Time PCR
detection system (Bio-Rad Laboratories, Inc., Hercules, CA)
was used for SCD1 and SREBP1c, and a Roche LighCycler
480 Instrument (Roche Diagnostics Manheim, Germany)
served for CB1, CB2, and FAAH mRNA quantification.
All samples were analysed in duplicate. The gene-specific
primers were purchased from Invitrogen Life Technologies
Inc. and are listed in Table 2. We optimized the PCR reaction
protocol according to manufacturer’s recommendations. For
SCD1 and SREBP1c, the thermal cycling program was 95◦C
for 2min, followed by 40 cycles at 95◦C for 25 s, at 60◦C
for 25 s, and at 72◦C for 40 s. For the quantification of CB1,
CB2, and FAAH mRNA, the following procedure was used.
Preincubation lasted 10min at 95◦C, followed by 45 cycles
of PCR at 95◦C for 15 s, 60◦C for 15 s, and 72◦C for 15 s.
Following PCR, the melting curve was completed to ensure
that only one PCR product was amplified per reaction. The
relative gene expression was calculated as a function of 2−ΔΔCt
and normalized for β-actin transcript level. The equation
used in the calculation was as follows: fold induction =
2−[ΔΔCt], where Ct = the threshold cycle, (i.e., the cycle
number at which the sample’s relative fluorescence rises
above background fluorescence) and ΔΔCt = [Ct gene of
interest (unknown sample) – Ct β-actin (unknown sample)
– Ct gene of interest (calibrator sample) – Ct β-actin
(calibrator sample)].
2.5.2. Western Blot Analysis. Liver tissue was prepared
by homogenization in RIPA (Radioimmunoprecipitation
Assay) buffer (50 nM Tris HCl pH8, 150 nM NaCl, 1%
NP-40, 0,5% sodium deoxycholate, 0,1% sodium dode-
cyl sulphate (SDS)) and 10−5 M protease inhibitors (phenyl-
methyl sulfonyl fluoride (PMSF), EDTA, and Pepstatin A)
then centrifuged at 10,000 g for 20min, at 4◦C. The super-
natants were collected, and protein concentrations were
determined using Bradford assay. Then, 30 μg of total protein
were applied to each well of 12% SDS polyacrylamide gel
and electrophoresed at 4◦C for 2 h at 130V. The resolved
protein bands were then transferred onto nitrocellulose
membranes (Hybond-C Extra; Amersham Biosciences) at
30V for 120min, at room temperature. The blots were
blocked overnight at 4◦C with blocking buffer (10% nonfat
milk in 10mmol/L Tris, pH 7.5, 100mmol/L NaCl, 0.1%
Tween 20). The blots were incubated for 1 h at room
temperature with primary antibody rabbit polyclonal anti-
SCD1 (1 : 2000) kindly provided by Dr. Juris Ozols, then
with horseradish peroxidase-labeled donkey antirabbit IgG
(1 : 10000 dilution, Amersham Biosciences UK) for 2 hours
at room temperature as secondary antibody. Protein loading
was normalized for β-actin (Sigma monoclonal anti-β-
actin antibody produced in mouse at 1 : 5000 dilution as
a primary antibody and horseradish peroxidase-conjugated
IgG anti-mouse as secondary antibody). Finally the blots
were visualized using the ECL (enhanced chemiluminescent,
Amersham RPN 2132) and exposed to autoradiography
film (Eugene, St-Laurent, QC). Density of the bands was
performed with the use of Photoshop software.
2.5.3. Liver Tissue Preparation for Lipid Analysis Using the
Folch Method [28]. Samples of 150–200mg frozen liver
tissue were homogenized in a saline buffer supplemented
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Table 3: Body weight, energy intake, sum of intra-abdominal fat pad weights (mesenteric, urogenital, and retroperitoneal), sum of 4 muscle
weights (soleus, plantaris, medial, and lateral gastrocnemius), plasma glucose, insulin, and leptin in sedentary (Sed) and trained (TR) rats
submitted to a fasting/refeeding protocol. Animals were fed a standard (SD) diet during 7wks and thereafter were starved for 24 h and fed a
SD diet for 24 h and starved for another 24 h and then fed the SD or the high-fructose (HFr) diet 24 h prior to sacrifice at the end of the 8th
week.
Diets SD diet HFr diet
Sed TR Sed TR
Body weight (g) 281 ± 8 292 ± 8 287 ± 9 291 ± 7
Energy intake (kcal/last 24 h) 84.7 ± 2.9 88.2 ± 4.2+ 57.9 ± 4.5&& 74.9 ± 4.9&&,+
Sum of intra-abdominal fat pad weights (g) 16.12 ± 1.9 15.2 ± 1.6+ (P = 0.058) 21.3 ± 2.37 14.8 ± 1.58+ (P = 0.058)
Sum of 4 muscle weights (g) 1.96 ± 0.05 2.08 ± 0.05+ 1.97 ± 0.04 2.07 ± 0.05+
Plasma glucose (mmol/L) 7.7 ± 0.3 8.1 ± 0.3 8.1 ± 0.4 7.3 ± 0.2
Plasma insulin (pM) 456 ± 67 573 ± 66 437 ± 65 447 ± 59
Plasma leptin (ng/mL) 2.62 ± 0.4 2.26 ± 0.2+ 3 ± 0.4 2.02 ± 0.2+
Values are means ± SE, n = 10 rats/group.
&&Significantly different from corresponding values under the SD diet, P < 0.01. +Significantly different from Sed rats under the same diet condition, P <
0.05.
with 1% antiprotease (PMSF, Pepstatin, leupeptin) and 1%
antioxidant (butylated hydroxytoluene, BHT). Lipid extrac-
tion from liver tissue was performed overnight at 4◦C with
the use of a 2 : 1 chloroform-methanol mixture (vol/vol).
Then, saline was added and the lower phase was removed
into glass vials and dried under a stream of nitrogen [29].
Tubes were immediately stored at −80◦C for further fatty
acid measurements.
2.5.4. Plasma and Liver Fatty Acid Composition Analysis and
SCD1 Desaturation Index. The method used for fatty acid
composition analysis was slightly adapted from the technique
described by Lepage and Roy [30]. Plasma (100 μL) or
prepared liver tissue (described above) was used for this
analysis. The samples were dissolved in 2mL methanol-
hexane 4 : 1 (v/v) mixture containing BHT and an internal
fatty acid standard (Nonadecanoic acid C19 : 1; NU-Check
Prep. Inc., Elysian, MN, USA). Then, 200 μL of acetyl-
chloride was added to each tube. Samples were hydrolysed
at 100◦C for 60min, followed by the addition of 5mL
of 6% K2CO3. The upper phase was extracted and then
analysed by gas chromatography. As described by Mainieri
et al. [29] using the quantitative values of palmitic acid
(C16 : 0), palmitoleic acid (C16 : 1), stearic acid (C18 : 0),
and oleic acid (C18 : 1), the desaturation index of SCD1 was
determined using the product/substrate ratio (C16 : 1/C16 : 0
and C18 : 1/C18 : 0).
2.5.5. Liver TAG. Liver TAG concentration was estimated
from glycerol released after ethanolic KOH hydrolysis by
a colorimetric method using commercial kits from Sigma
(St. Louis, Missouri, USA). Although this method does not
discriminate between glycerol from phospholipids or TAG,
Frayn and Maycock [31] have shown that omitting removal
of phospholipids leads to only a ± 2% error in the determi-
nation of muscle TAG. Thus, although a small amount of free
glycerol may be produced from hydrolysis of phospholipids,
it is considered negligible.
2.5.6. Plasma FFA and TAG. Plasma total free fatty acid
(FFA) concentrations were measured by a colorimetric assay
with commercially available kits from Roche Diagnostics
(Penzberg, Germany). Plasma TAG was measured using a
colorimetric method (Sigma; St. Louis, Missouri, USA).
2.5.7. Plasma Glucose, Insulin, and Leptin. Plasma glucose
concentrations were determined with the use of a glucose
analyser Yellow Springs Instruments 2300 (Yellow Springs,
Ohio, USA). Plasma insulin and leptin concentrations were
measured with commercially available radioimmunoassay
kits (Linco Research, St-Charles, Missouri, USA).
2.6. Statistical Analysis. Values are expressed as means ± S.E.
Statistical analyses were performed with the use of a two-way
ANOVA for nonrepeated measures using training status and
diet as main effects. Fisher LSD post hoc test was applied
where appropriate, and P values < 0.05 were considered
significant.
3. Results
Feeding rats an HFr diet after starvation failed to induce
changes in body weight, abdominal adiposity, muscle weight,
circulating glucose, insulin, and leptin, even though it
decreased energy intake (P < 0.01) (Table 3). Exercise train-
ing, however, was associated with a significant increase in
energy intake as well as in the sum of 4 muscle weights and
with a decrease in intra-abdominal adiposity and in plasma
leptin levels under the two diet conditions (P < 0.05).
HFr compared to SD refeeding resulted in higher (P <
0.05) gene expression of SCD1, SREBP1c, and CB1 along
with protein content of SCD1 (Figure 1). Training, however,
had no effect on the expression of any of these molecular
markers.
As expected, HFr refeeding resulted in higher liver and
plasma TAG as well as plasma FFA levels (Figure 2). Although
liver TAG levels were not affected by training, plasma TAG
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Figure 1: Gene expression of hepatic stearoyl-CoA desaturase1 (SCD1), sterol regulatory element-binding protein1c (SREBP1c), endo-
cannabinoid receptors (CB1 and CB2), fatty acid amide hydrolase (FAAH), and protein content of liver SCD1 relative to β-actin in sedentary
(Sed) and trained (TR) rats submitted to a fast/refeeding protocol. Animals were fed a standard (SD) diet during 7wks and thereafter were
starved for 24 h and fed with the SD diet for 24 h and starved for another 24 h and then fed with the SD or the high-fructose (HFr) diet 24 h
prior to sacrifice at the end of the 8th week. Values are means± SE with n = 10 rats/group except for SCD1 protein level (n = 4–6 rats/group).
&: significantly different from corresponding values under the SD diet, P < 0.05, &&: P < 0.01.
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Figure 2: Liver and plasma triacylglycerol (TAG) and plasma free fatty acid (FFA) in sedentary (Sed) and trained (TR) rats submitted to a
fast/refeeding protocol. Animals were fed a standard (SD) diet during 7wks and thereafter were starved for 24 h and fed with the SD diet
for 24 h and starved for another 24 h and then fed with the SD or the high-fructose (HFr) diet 24 h prior to sacrifice at the end of the 8th
week. Values are means ± SE with n = 10 rats/group. &: significantly different from corresponding values under the SD diet, P < 0.05, &&:
P < 0.01. +: significantly different from Sed rats under the same diet condition, P < 0.05, ++: P < 0.01.
and FFA levels were, respectively, higher (P < 0.05) and lower
(P < 0.01) in TR animals refed with the HFr diet.
SCD1 fatty acid desaturation indexes (C16 : 1/C16 : 0 and
C18 : 1/C18 : 0) in the liver were significantly (P < 0.01) in-
creased exclusively in TR animals refed the HFr diet as a
result of a synergetic effect of TR and HFr refeeding (Figures
3(a) and 3(b)). In plasma, HFr refeeding induced an increase
in C16 : 1/C16 : 0 in both Sed and TR rats and an increase in
C18 : 1/C18 : 0 only in TR rats (Figures 3(c) and 3(d)).
4. Discussion
In an attempt to further understand the role played by
regular exercise training on liver fat metabolism and accu-
mulation, we designed the present study to determine if an
exercise training program may affect the acute handling of
a fructose load by the liver. Using a fasting/HFr refeeding
approach, we found that gene expression of hepatic molec-
ular markers of the lipogenesis pathway and as well liver fat
accumulation were highly but similarly increased by the HFr
refeeding in Sed as well as in TR rats. To go one step further,
we measured the ratio of monounsaturated to saturated fatty
acids, which is used as a surrogate marker for SCD1 activity
in liver, thus providing a physiological assessment of the
fructose disposal by the liver and fatty acid partitioning [14,
32]. We report for the first time that, following the ingestion
of a fructose load, the SCD1desaturation indexes were higher
in liver (C16 : 1/C16 : 0 and C18 : 1/C18 : 0) and in plasma
(C18 : 1/C18 : 0) of TR compared to Sed animals. This finding
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Figure 3: Stearoyl-CoA desaturase1 (SCD1) fatty acid desaturation indexes expressed under the form of the ratio of monounsaturated
(C16 : 1, C18 : 1) over saturated (C16 : 0, C18 : 0) fatty acids measured in liver and plasma of sedentary (Sed) and trained (TR) rats submitted
to a fast/refeeding protocol. Animals were fed a standard (SD) diet during 7wks and thereafter were starved for 24 h and fed with the SD diet
for 24 h and starved for another 24 h and then fed with the SD or the high-fructose (HFr) diet 24 h prior to sacrifice at the end of the 8th
week. Values are means ± SE, n = 10 rats/group for plasma and n = 5 rats/group for liver desaturation indexes. &&: significantly different
from corresponding values under the SD diet, P < 0.01. ++: significantly different from Sed rats under the same diet condition, P < 0.01.
indicates that training affects the acute handling of a fructose
load by providing a higher rate of conversion of de novo
synthesized saturated fatty acids to the monounsaturated
form.
The HFr refeeding in Sed animals did not affect the fatty
acids desaturation indexes measured in the liver (Figures
3(a) and 3(b)). This indicates that the HFr diet did not
result in a change in the ratio of saturated versus monoun-
saturated fatty acids accumulated in the liver. However, the
C16 : 1/C16 : 0 desaturation index of Sed rats refed with the
HFr was highly increased in plasma, suggesting an increased
liver exportation of the fatty acids under the desaturated
form. Several studies have demonstrated that fatty acids
originating from different sources appear to be managed
differently in the liver with regard to their use for storage
or secretion [33, 34]. More specifically, it seems that newly
synthesized fatty acids are channelled preferentially into
very-low-density lipoproteins for exportation [35]. Plasma
TAG and FFA plasma levels were accordingly increased by
the HFr refeeding in Sed rats. However a somewhat different
picture is found in TR rats. First, liver SCD-1 desaturation
indexes were highly increased following training without any
effects on liver TAG levels. This indicates that although the
same quantity of fat was accumulating in liver of Sed and
TR animals after the HFr refeeding, more of the fatty acids
stored in liver of TR rats were under the desaturated form.
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This as such provides new evidence that training affect, the
acute handling of a fructose load. It might be argued that
the increased desaturation ratio in liver of TR rats might be
due to a decreased exportation of desaturated fatty acids.
This possibility, however, is not supported by the finding
that the C16 : 1/C16 : 0 desaturation ratio in plasma was
similar between Sed and TR rats and the C18 : 1/C18 : 0 ratio
was higher in TR than in Sed animals. The present data,
therefore, support the interpretation that exercise training
may influence the acute management of a substrate load
such as fructose by changing the partitioning of newly
synthesized fatty acids. Supporting this view is the recent
report that physical inactivity favours the accumulation
of palmitate (C16 : 0) in muscle fat and decreases dietary
palmitate but not oleate (C18 : 1) oxidation thus leading to
the deterioration of insulin signalling [22].
The higher levels of fatty acids under the desaturated
form in liver of TR rats refed with the HFr load may
present some advantages. Recently, Li et al. [36] reported
that SCD1 plays a key role in prevention of steatohepatitis
by partitioning excess lipid into monounsaturated fatty acids
(MUFAs) that can be safely stored. This indicates that
training favouring the formation of fatty acids that are mostly
unsaturated in liver could represent a molecular mechanism
of exercise-training-induced metabolic protection in liver.
Newly synthesized MUFAs C16 : 1 and C18 : 1 are the most
abundant fatty acids founds in TAG molecules [37]. In this
regard, exercise training might favour the conversion of the
de novo synthesized fatty acids that are cytotoxic molecules
into a form more easily transferrable to TAG, known to be
biologically inert molecules [38, 39].
Exercise training did not, under the present acute dietary
manipulations, result in lower levels of liver fat accumu-
lation. The effects of exercise training in reducing liver
fat accumulation under long-term high-fat diets have been
reported in several studies [17, 40]. The absence of effects
of exercise training on liver fat accumulation in the present
study is most likely due to the powerful effect of the HFr load
on lipogenesis. HFr refeeding, whether in Sed or TR rats,
was associated with an increase in hepatic gene expression of
SCD1, SREBP1c, and the endocannabinoids CB1 receptors.
It has been reported that the activation of CB1 receptors
in liver stimulates de novo lipogenesis through induction
of SREBP1c and its target enzymes [12]. Recent data in
liver-specific CB1 knockout mice indicate that hepatic CB1
receptors are required for the development of diet-induced
steatosis by increasing de novo lipogenesis and inhibiting
fatty acid oxidation [11]. In agreement with this statement,
our data show, for the first time, that gene expression of
CB1, and to a lesser extent CB2, was increased in liver of
fasted and fructose refed animals in comparison to those
refed the SD diet. Additionally, it has been reported that lipid
accumulation in liver may also occur by reduced expression
and/or activity of fatty acid amide hydrolase (FAAH), one of
the endocannabinoid degrading enzymes [24]. The present
results, however, do not indicate any effects of the high-
fructose diet on the gene expression of the FAAH enzyme.
The fact that SCD1 gene expression and protein content
in liver were not changed in TR compared to Sed rats under
the HFr refeeding might at first glance contradict the finding
of higher SCD1 desaturation indexes measured in the same
rats. As stated above, the SCD1 index reflects the activity of
SCD1. It is possible that since the HFr load highly stimulated
the lipogenesis pathway that the discrimination between the
TR and the Sed state might be possible only at the activity
level.
An intriguing observation that needs to be addressed
is the fact that several hours after the HFr refeeding, TR
rats had higher plasma TAG and lower plasma FFA levels
than their Sed counterparts. The present study provides no
information on VLDL secretion rate. However, since liver
TAG levels were similar in TR and Sed rats, it is unlikely
that a difference in VLDL synthesis and/or secretion rate is
responsible for the higher plasma TAG levels found in TR
animals. In search of a different explanation, we must first
acknowledge the fact that energy intake was ∼30% higher in
TR than in Sed rats refed the HFr diet. On a speculative basis,
it is possible that the lower plasma TAG levels found in Sed
compared to TR rats might be linked to a greater ability of
Sed rats to store fat in peripheral adipose tissue under the
present acute nutritional manipulations. Although the inter-
diet comparisons did not reach the statistically significant
level, the HFr compared to the SD refeeding seems to have
resulted in higher intra-abdominal fat accumulation in Sed
(from ∼16 to 21 g) than TR rats (from 16 to 15.8 g; Table 3).
In connection with this, higher plasma FFA levels measured
in Sed compared to TR rats refed the HFr could result from
a higher rate of basal lipolysis due to the higher adipocyte fat
accumulation [41].
In summary, exercise training is associated with higher
liver (C16 : 1/C16 : 0 and C18 : 1/C18 : 0) and plasma
(C18 : 1/C18 : 0) SCD1 desaturation indexes in rats submit-
ted to a 2-day fast/refeeding protocol using a high-fructose
diet in the second day. Gene expression of lipogenic
molecular markers including hepatic endocannabinoid re-
ceptors, transcription factor SREBP1c, and SCD1 protein
content was increased to a similar in extent in Sed and TR
rats refed with the HFr diet. It is concluded that the pattern
of management of the HFr load in a fast/refed protocol is
modified in exercise trained animals so as to provide more
fatty acids under the unsaturated form in liver and plasma.
These data support the contention that exercise training
positively modifies the handling of an acute substrate load.
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Background and Aims. This study examined if exercise and omega-3 fatty acid (n3PUFA) supplementation is an effective treatment
for hepatic steatosis in obese, hyperphagic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Methods. Male OLETF rats were
divided into 4 groups (n = 8/group): (1) remained sedentary (SED), (2) access to running wheels; (EX) (3) a diet supplemented
with 3% of energy from fish oil (n3PUFA-SED); and (4) n3PUFA supplementation plus EX (n3PUFA+EX). The 8 week treatments
began at 13 weeks, when hepatic steatosis is present in OLETF-SED rats. Results. EX alone lowered hepatic triglyceride (TAG) while,
in contrast, n3PUFAs failed to lower hepatic TAG and blunted the ability of EX to decrease hepatic TAG levels in n3PUFAs+EX.
Insulin sensitivity was improved in EX animals, to a lesser extent in n3PUFA+EX rats, and did not differ between n3PUFA-SED
and SED rats. Only the EX group displayed higher complete hepatic fatty acid oxidation (FAO) to CO2 and carnitine palmitoyl
transferase-1 activity. EX also lowered hepatic fatty acid synthase protein while both EX and n3PUFA+EX decreased stearoyl CoA
desaturase-1 protein. Conclusions. Exercise lowers hepatic steatosis through increased complete hepatic FAO, insulin sensitivity,
and reduced expression of de novo fatty acid synthesis proteins while n3PUFAs had no effect.
1. Introduction
It is estimated that 20–40% of the general population
and 50–90% of obese people have nonalcoholic fatty liver
disease (NAFLD) [1, 2]. The presence of NAFLD has been
described as an independent risk factor for the development
of cardiovascular disease [3–5], and it often accompanies
other obesity-related diseases such as type 2 diabetes and
is considered the hepatic manifestation of the metabolic
syndrome [6]. Further, NAFLD is associated with increases
in all-cause and liver-related mortality [7, 8]. As a result,
the examination of affordable treatment options for NAFLD,
such as exercise or omega-3 polyunsaturated fatty acid
(n3PUFA) supplementation, is becoming more imperative.
Unfortunately, there is a paucity of studies investigating exer-
cise and exercise combined with n3PUFA supplementation
as treatments for NAFLD. Most exercise research has been
focused on prevention, and not on treatment or reversal of
preexisting NAFLD.
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We have previously used the Otsuka Long-Evans
Tokushima Fatty (OLETF) rats to investigate NAFLD
because they spontaneously develop obesity, insulin resis-
tance, and NAFLD which progressively worsens with advanc-
ing age [9, 10]. OLETF rats lack the cholecystokinin-1
receptor resulting in hyperphagia due to defective satiety
signaling [11]. Further, a novelty of this particular model
is their intrinsic aptitude for exercise (EX) on voluntary
running wheels, a characteristic that is uncommon in obese
rodent models. We have previously shown that EX on
voluntary wheel running beginning at 4 weeks of age in
OLETF rats prevents the development of hepatic steatosis,
effects that were associated with prevention of insulin
resistance and increased hepatic fatty acid oxidation (FAO)
[9]. Moreover, we have established that locking of the wheels
and ceasing daily EX in OLETF rats quickly activate a
subgroup of precursors and processes known to initiate
hepatic steatosis, including decreased hepatic mitochondrial
oxidative capacity, increased hepatic expression of de novo
lipogenesis proteins, and increased hepatic malonyl CoA
levels [12]. Other labs have also shown that exercise can
prevent fatty liver in rodents fed a high-fat-diet to induce
obesity [13, 14]. Although we and others have established
that daily exercise is an invaluable intervention to prevent
NAFLD, it remains unknown if exercise is an effective
treatment strategy for preexisting NAFLD.
Dietary polyunsaturated fatty acids (n3PUFAs) have
also been studied as a treatment for NAFLD. n3PUFAs
both activate a transcription factor that is important for
hepatic oxidative capacity (peroxisome proliferator-activated
receptor (PPARα)) and inactivates a master regulator of
hepatic lipid synthesis (sterol regulatory element binding
protein (SREBP)-1c) in rodents [15–22] and humans [23,
24]. This dual action on hepatic metabolism suggests that
n3PUFAs could lower hepatic fat content. In OLETF rats,
dietary intake of n3PUFAs beginning at 5 weeks of age
prevented hepatic steatosis by decreasing the activity of
lipogenic enzymes such as fatty acid synthase (FAS) and
stearoyl CoA desaturase (SCD)-1 and decreasing mRNA
expression of several key lipogenic genes including SREBP-
1c and acetyl CoA carboxylase (ACC) [25]. The authors
also found that mRNA expression and activity of CPT, a
protein that is controlled by PPARα, were increased in the
liver of n3PUFA-fed OLETFs [25]. These results indicate
that n3PUFAs were effective at preventing increased liver
TAG accumulation in OLETF rats; however, this study also
addressed prevention and not treatment of NAFLD.
Treatment of NAFLD with n3PUFAs has also been
examined previously. Seven days of dietary consumption of
n3PUFAs led to reductions, but not complete reversal, of
hepatic steatosis, and systemic insulin resistance in ob/ob
mice, associated with the down-regulation of SREBP-1c [19].
The authors also observed increased activation of PPARα and
its associated gene targets suggesting increased β-oxidation
in the liver, but lacked a quantitative measure of FAO. In
another study, dietary intake of n3PUFAs attenuated, but
was again not able to completely reverse, liver TAG content
following high-fat-diet-induced hepatic steatosis [20].
To our knowledge, we are unaware of any studies that
have examined the individual and combined effects of exer-
cise and n3PUFA supplementation on hepatic mitochondrial
FAO and treatment of NAFLD. Thus, the purpose of this
study was to examine the individual and combined effects
of exercise and the dietary intake of omega-3 fatty acids
(3% of energy from fish oil) to treat preexisting hepatic
steatosis in OLETF rats. We also examined the effects of
these treatments on factors known to play a role in the
development of hepatic steatosis including peripheral insulin
sensitivity, hepatic FAO, and markers of hepatic lipogenesis.
We hypothesized that both exercise and n3PUFAs would
reverse or attenuate progression of NAFLD in obese rats
and that the combination of treatments would have an even
greater effect on treating NAFLD.
2. Methods
2.1. Study Design. The animal protocol was approved by the
Institutional Animal Care and Use Committee at the Univer-
sity of Missouri. Male OLETF rats were generously provided
by the Tokushima Research Institute, Otsuka Pharmaceutical
(Tokushima, Japan) and arrived at 4 weeks of age. Rats
were given ad libitum access to normal chow food (Purina
Formulab Diet, 5008) and water in a temperature- and light-
controlled room (12 h light-12 h dark cycle). At 13 weeks
of age, an age when obesity, insulin resistance, and NAFLD
are present in sedentary OLETF rats [10], OLETFs were
randomly divided into 4 groups (n = 8/group): (1) remained
sedentary (SED) on normal chow, (2) was provided access to
voluntary running wheels (EX) with normal chow, (3) was
provided diet supplemented with 3% of energy from fish
oil (n3PUFA-SED), and (4) had access to running wheels
and diet supplemented with 3% of energy from fish oil
(n3PUFA+EX). Thus, treatments began at 13 weeks of age
and ended at 20 weeks of age when rats were euthanized.
Food consumption and body weights were assessed weekly,
and running distances (wheels outfitted with a Sigma Sport
BC 800 bicycle computer (Cherry Creek Cyclery, Foster Falls,
VA, USA) for measuring daily running activity) in EX and
n3PUFA-EX rats were measured daily following the end of
the dark cycle during the 8-week treatment period. After
being fasted and having wheels locked for a 5 h period, rats
were anesthetized with sodium pentobarbital (100mg/kg),
tissue and blood were collected, fat pads were weighed, and
rats were euthanized by exsanguination.
2.2. Diet. The normal chow diet used was Formulab 5008
(Purina Mills, St. Louis, Mo, USA) which we have used
in previous studies in which the OLETF rats develop
steatosis [9, 10]. The n3PUFA diet was custom-formulated
at the University of Missouri using an AIN-93G diet
supplemented with 3% of energy from menhaden fish oil.
The menhaden fish oil was kindly donated by Omega
Protein, Inc. (Houston, Tex, USA) and was stabilized with a
synthetic antioxidant (0.2 g/kg tertiary butyl-hydroquinone
(TBHQ)) and 1000mg/kg mixed tocopherols to protect it
from autooxidation. The percent of energy provided by fat
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was the same between the Formulab 5008 and n3PUFA diet,
16.7%, respectively.
2.3. Intraperitoneal Glucose Tolerance Tests. Baseline glucose
values were determined following a 12 h overnight fast one
week prior to sacrifice (19 weeks of age). Glucose (2.0 g/kg)
was then administered intraperitoneally, and tail blood draws
were taken prior to and 15, 30, 45, 60, and 120min following
the bolus of glucose as performed previously by our group
[26].
2.4. Dual-Energy X-Ray Absorptiometry (DEXA). Whole
body composition was determined using a Hologic QDR-
1000/w DEXA machine calibrated for rats as performed
previously by our group [27].
2.5. Serum Measures. The concentrations of glucose (Sigma
Aldrich, St. Louis, Mo, USA), insulin (Millipore, Biller-
ica, Mass, USA), β-hydroxybutyrate (Stanbio Laboratory,
Boerne, Tex, USA), triglycerides (Sigma Aldrich), and free
fatty acids (Wako, Richmond, Va, USA) in plasma were
measured using commercially available kits.
2.6. Liver Tissue Procedures. Livers were quickly excised
from anesthetized rats and were either immediately freeze-
clamped in liquid nitrogen, placed in 10% formalin, or
placed in ice-cold isolation buffer and then homogenized as
previously described [9].
2.7. Fatty Acid Oxidation. Fresh tissue fatty acid oxidation
(FAO) using radiolabeled 14C palmitate (Perkin Elmer,
Boston, Mass, USA) was performed as previously described
[27]. Briefly, both 14CO2, representing complete fatty acid
oxidation, and 14C-labeled acid soluble metabolites (14C
ASM), representing incomplete fatty acid oxidation, were
collected in the previously described trapping device and
then counted on a liquid scintillation counter. In addition
to the 14C palmitate, the reaction buffer contained a final
concentration of 50 μM cold palmitate and 0.5% bovine
serum albumin.
2.8. Enzyme Assays. Carnitine palmitoyl transferase-1 (CPT-
1) activity, β-hydroxy-acyl-CoA dehydrogenase activity (β-
HAD), and citrate synthase activity assays were performed as
described previously by our group [27].
2.9. Hepatic Nuclear Isolation. Nuclear extraction of fresh
liver tissue was performed using a commercially available kit
(Marligen Biosciences, Ijamsville, Md, USA). Briefly, fresh
tissue was immediately placed into hypotonic lysis buffer,
homogenized, washed, vortexed, and centrifuged. Super-
natant containing the cytoplasmic extracts was removed.
Each sample was washed by centrifugation until the super-
natant was clear. Samples were incubated on ice followed
by a 30min high-speed centrifugation at 4◦C. Supernatant
was removed representing the nuclear extract and stored at
−80◦C.
2.10. Hepatic TAG and DAG Analysis. Hepatic fatty acids
were extracted using a modified Folch method [28]. Briefly,
liver tissue was homogenized in ice-cold Trizma/EDTA buffer
and lipids were extracted in chloroform/methanol/acetic acid
(2 : 1 : 0.15). Extracted lipids were then run on a thin-layer
chromatography (TLC) silica plate in a tank containing
hexane, diethyl ether, and acetic acid (70 : 30 : 1). Triglyceride
and diacylglycerol fractions were scraped from the TLC
plate and were then methylated by incubating with toluene,
methanol, and acetyl chloride (0.5 : 1.2 : 0.1) at 100◦C for
60min and separated in hexane. Fatty acid methyl esters
were analyzed by gas chromatography (Agilent Technologies,
Wilmington, De, USA).
2.11. Liver Histology. Hematoxylin and eosin (H&E) staining
was performed on formalin-fixed paraffin-embedded section
of liver as described previously to assess lipid vacuolization
[29].
2.12. Western Blotting. Western blots were performed to
detect protein levels of PPARα (Santa Cruz Biotechnology,
Santa Cruz, Calif, USA), PPARδ (Thermo Scientific, Rock-
ford, Il, USA), PPARγ (Cell Signaling, Beverly, CA), SREBP-
1c (Santa Cruz Biotechnology), fatty acid synthase (FAS)
(Cell Signaling), acetyl coenzyme A carboxylase (ACC) (Cell
Signaling), and stearoyl CoA desaturase (SCD)-1 (Alpha
Diagnostic International, San Antonio, Tex, USA) as per-
formed previously [9]. Liver samples were homogenized in
ice-cold lysis buffer, separated by SDS-PAGE gels, transferred
to PVDF membranes, and probed with primary antibodies.
Protein bands were quantified using a densitometer and band
densities were corrected for total protein loaded by staining
with 0.1% amido black (Sigma) as described previously [9].
2.13. Gene Expression. Quantitative RT-PCR was performed
as previously described for mRNA expression of PPARα and
PPARδ [26]. Briefly, on the day of sacrifice, fresh tissue
was collected and placed in RNAlater (Ambion, Austin,
Tex, USA) stored at 4◦C for 24 h and then stored at
−20◦C. Liver samples were pulverized in RLT buffer using
the QIAGEN TissueLyser system (Valencia, Calif, USA).
RNA was then isolated using a commercially available kit
(QIAGEN, Valencia, Calif, USA). Reverse transcription and
cDNA synthesis were performed according to the manufac-
turer instructions (Promega, Madison, Wis, USA). TaqMan
Master Mix (Applied Biosystems, Foster City, Calif, USA)
for gene targets PPARα and PPARδ were loaded into a 96-
well microplate along with the cDNA sample (5 μg/μL) and
placed into the ABI 7000 Sequence Detection System for
polymerization. Results were quantified relative to β-actin.
Critical threshold (Ct) values for the housekeeping gene did
not differ among groups (data not shown).
2.14. Statistical Analysis. Treatment differences were ana-
lyzed by one-way analysis of variance (ANOVA) with main
effect significance set at P < 0.05. Significant main effects
were then followed up by least significant difference (LSD)
post hoc comparisons (SPSS 17.0). Data are presented as
means ± SE, and significance was set at P < 0.05.
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Table 1: Animal and serum characteristics.
SED EX n3PUFA-SED n3PUFA+EX
Final body weight (g) 617.1± 20.0a 462.0± 10.5b 571.6± 10.3c 512.1± 17.5d
Body fat (%) 31.9± 0.9a 11.3± 1.6b 29.5± 1.1a 18.8± 1.3c
Fat pad mass (g) 33.1± 2.0a 9.2± 1.6b 26.4± 1.7c 16.4± 1.8d
Food intake (g) 228.2± 7.5a 192.2± 4.0b 226.6± 5.8a 178.5± 3.2b
Food wt (g)/BW (g) 0.40± 0.00a 0.45± 0.01b 0.40± 0.00a 0.39± 0.01a
Caloric intake (kcal) 947.0± 31.0a 797.8± 16.7b 853.2± 21.9b 672.1± 11.9c
Calories (kcal)/BW (g) 1.67± 0.01a 1.84± 0.05b 1.52± 0.02c 1.48± 0.03c
Triglycerides (mg/dL) 123.7± 17.6a 62.1± 9.4b 59.4± 5.4b 36.9± 4.6b
Free fatty acids (μmol/L) 422.6± 38.4a 199.3± 25.8b 263.0± 25.3b 193.4± 26.5b
Glucose (mg/dL) 396.0± 14.1a 255.9± 16.0b 311.9± 45.1b 239.2± 14.5b
Insulin (ng/mL) 15.0± 1.9a 10.0± 1.3b 11.8± 1.6a,b 7.6± 0.9b
Heart wt/body wt (mg/g) 2.5± 0.10a 3.5± 0.01b 2.7± 0.10a 3.1± 0.10b
Values are means ± SE (n = 8). Values with different letter superscripts are significantly different from each other (P < 0.05). Fat pad mass: omental +
retroperitoneal fat pads; BW: body weight.
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Figure 1: Running distance and body weights. Weekly run distance (a) during the 8 week treatment intervention and weekly body weight (b).
Values are means ± SE (n = 8). ∗EX and n3PUFA+EX are significantly different from SED and n3PUFA-SED (P < 0.05). #EX is significantly
different from all groups, and n3PUFA+EX is significantly different than SED and n3PUFA-SED.
3. Results
3.1. Animal and Serum Characteristics. Final body weight
and fat pad mass (omental + retroperitoneal) were sig-
nificantly different among all groups (Table 1). Body fat
percentage was highest in the SED and n3PUFA-SED rats;
EX rats had the lowest body fat percentage, over 2.5fold
lower than SED and n3PUFA-SED and 1.6fold lower than
n3PUFA+EX. Fat pad mass mirrored the body fat percentage
measures except that n3PUFA-SED was lower than SED.
Weekly food intake (grams) was reduced in the EX and
n3PUFA+EX groups as compared to SED and n3PUFA-SED.
However, when weekly food intake (grams) was normalized
to body weight, the EX group consumed more than the
SED, n3PUFA-SED, and n3PUFA+EX groups. Weekly caloric
intake per body weight was also highest in the EX compared
to all other groups. In addition, the SED group consumed
more Kcal per body weight than the two groups who received
n3PUFA supplementation. All 3 treatment conditions sig-
nificantly lowered circulating TAG and FFAs compared with
SED rats.
3.2. Weekly Run Distance and Body Weight. EX and
n3PUFA+EX rats were given access to running wheels at
13 weeks of age. There were no differences in weekly
run distances between the two groups (Figure 1(a)). Peak
running distances in both groups were approximately 56 and
55 km per week (approximately 8 km per night) at 16 weeks
and slowly declined to about 34 and 33 km per week (∼5 km
per night) by 20 weeks of age. As shown in Figure 1(b), EX
and n3PUFA+EX rats showed a decline in body weight the
first two weeks following introduction to wheel running and
then began gaining weight again while SED and n3PUFA-
SED rats continued to gain weight during the 8 weeks of
treatment.
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Figure 2: Hepatic fat storage. Fat accumulation in the liver as shown by liver triglyceride content (a), liver diacylglycerol content (b), liver
n3PUFA content (EPA + DHA) (c), and representative images of hematoxylin and eosin staining for lipid vacuolization (d). Values are means
± SE (n = 8). Values with different letter superscripts are significantly different from each other (P < 0.05).
3.3. Hepatic Steatosis. Hepatic TAG content from previously
studied 13-week-old OLETF-SED rats (n = 8) was used
as a baseline measure of hepatic steatosis allowing us to
determine if the 8-week treatments could reverse steatosis.
As shown in Figure 2(a), EX rats had lower TAG content
at 20 weeks of age as compared to the baseline TAG
content of SED-12 wk rats (P = 0.03), indicating EX
effectively treated NAFLD. Although the beneficial effects
of EX were partially blunted in the n3PUFA+EX animals,
liver TAG content was significantly lower than SED-20 wk
(P = 0.001). Unexpectedly, n3PUFA supplementation in
sedentary, hyperphagic rats exacerbated hepatic steatosis
above that measured in both SED groups (P < 0.05;
Figure 2). Hepatic DAG content (Figure 2(b)) followed sim-
ilar trends as TAG content, with EX and n3PUFA+EX both
offering protection against the accumulation of DAGs in the
liver as compared to SED and n3PUFA-SED. The n3PUFA
content eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) were measured in the liver and showed that EPA
and DHA were incorporated into the liver at a higher level
in n3PUFA-fed rats with n3PUFA-SED having the highest
content (Figure 2(c)). Representative images of H&E staining
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for lipid vacuolization (Figure 2(c)) demonstrate a visual
presence of steatosis in n3PUFA-SED and SED rats as shown
by the large size and number of lipid droplets, whereas EX
and n3PUFA+EX displayed noticeably less lipid droplets.
3.4. Systemic Insulin Sensitivity. Blood glucose and insulin
levels were elevated in SED rats as compared to EX, n3PUFA-
SED, and n3PUFA+EX (Table 1). Glucose responses to the
tolerance test are shown in Figure 3(a). Glucose and insulin
AUCs during the IPGTT did not differ between n3PUFA and
SED groups, whereas EX rats had significantly lower glucose
and insulin AUCs (P < 0.01), and n3PUFA-EX rats only had
lower insulin AUCs (P < 0.05) as shown in Figures 3(b) and
3(c).
3.5. Hepatic Mitochondrial Function and Fatty Acid Oxida-
tion. Only the EX group had higher CPT-1 activity than SED
(Figure 4(a); P < 0.05). EX and n3PUFA+EX had higher
citrate synthase activity followed by SED (Figure 4(e)), and
there were no differences among groups in β-HAD activity,
though a main effect of treatment groups versus SED
approached significance (Figure 4(f); P = 0.059). Rats in
the n3PUFA-SED and n3PUFA+EX groups had significantly
higher total FAO (14CO2 + 14C ASM) as compared to
SED and EX rats (Figure 4(c)). This elevation in total
FAO was due to elevated incomplete fatty acid oxidation
as shown by higher ASM production (data not shown).
Further, in the presence of etomoxir, which inhibits CPT-
1 thereby ceasing the transport of long-chain fatty acids
to the mitochondria, n3PUFA-SED and n3PUFA+EX had
higher rates of FAO than the EX group but not the SED
group (Figure 4(d)). This suggests that the dietary intake
of n3PUFAs increases extramitochondrial total FAO in both
SED and EX conditions. In addition, EX was the only
group to have significantly higher complete FAO (14CO2) as
compared to SED, n3PUFA-SED, and n3PUFA+EX as shown
in Figure 4(b).
3.6. Hepatic Transcription Factors and Fatty Acid Synthesis
Pathway. PPARα mRNA expression was significantly lower
in EX and n3PUFA+EX (Figure 5(a)). The expression of
PPARδ, a transcription factor associated with mitochondrial
biogenesis and fatty acid oxidation, was 3-fold higher in
EX as compared to SED, n3PUFA-SED, and n3PUFA+EX
(Figure 5(b)). However, there were no differences in protein
expression of PPARα or δ among groups as shown in Figures
5(c) and 5(d). The nuclear protein content of SREBP-1c did
not differ among groups, although there was a trend toward
significance (P = 0.09) as seen in Figure 6(a). There also
was a trend (P = 0.09) for a main effect for treatment on
ACC protein content. However, the EX rats had significantly
lower FAS protein content (P = 0.02) as compared to SED,
n3PUFA-SED, and n3PUFA+EX. There were no differences
in PPARγ protein content among groups (representative
western blot shown in Figure 6(f)). EX rats also had the
lowest protein content of SCD-1 as compared to the other
groups (Figure 6(d)). SCD-1 desaturase index was lowest
in EX and highest in n3PUFA-SED rats as estimated by
product (16 : 1) to substrate (16 : 0) ratio for the enzyme
(Figure 6(e)).
4. Discussion
The primary objectives of the current study were to deter-
mine if exercise and n3PUFA supplementation, alone or in
combination, could effectively treat hepatic steatosis in obese
OLETF rats and to determine if these treatment strategies
were associated with changes in insulin sensitivity, hepatic
mitochondrial FAO, or markers of hepatic lipogenesis. The
major findings include the following: (1) exercise treat-
ment reversed preexisting hepatic steatosis in association
with elevated hepatic complete FAO and CPT-1 activity,
improved systemic insulin sensitivity, and decreased markers
of hepatic lipogenesis; (2) n3PUFAs supplemented at 3%
of diet increased TAG accumulation in the liver and, when
combined with exercise n3PUFAs, did not lead to additive
health benefits, but instead partially blunted the beneficial
effects of exercise to reduce hepatic TAG accumulation and
improve insulin sensitivity.
EX was the only treatment that reversed liver TAG
content below the pretreatment levels measured in 13-week-
old sedentary OLETF animals. It is likely that EX lowered
hepatic steatosis in part by slowing gains in body weight and
fat mass that normally occur in SED conditions. However,
the data also supports the notion that EX induced a hepatic
metabolic phenotype that played a role in reducing steatosis
as well. Evidence suggests that EX increased both the mito-
chondrial entry rate (higher CPT-1 activity (Figure 4(a))
and complete catabolism of long-chain fatty acids (increased
complete palmitate oxidation to CO2 (Figure 4(b)). The
increase in complete oxidation is likely due to a more efficient
coupling of increased β-oxidation and TCA cycle flux. EX
also lowered extramitochondrial hepatic FAO (oxidation that
occurs in the presence of CPT-1 inhibition with etomoxir
(Figure 4(d)). Our assumption is that extramitochondrial
oxidation is primarily driven by peroxisomes, organelles that
break down longer chain fatty acids so that they can then
be oxidized in the mitochondria. Peroxisomal activity has
previously been shown to be higher in the SED OLETF [30]
and when not paired with increased mitochondrial FAO [31–
33] could lead to the accumulation of fatty acid metabolites
and oxidative stress.
Livers were examined 5 hours after the last exercise bout,
opening the possibility that the exercise-induced adaptations
were primarily due to the last bout of exercise rather than
a result of chronic training. In a previous study from our
group, OLETF rats exercised on voluntary running wheels
for XX weeks before we locked the wheels to stop exercise
[12]. We then examined hepatic responses 5 hours, 53 hours
(2 days), and 173 hours (7 days) after the last exercise bout
allowing us to determine if 2 or 7 days of inactivity led to
different outcomes than the group studied 5 hours after the
last bout. In addition, all 3 groups were also compared to
OLETFs who were never provided access to running wheels.
Most measures of mitochondrial content were unchanged
by 7 days of inactivity and were still higher than sedentary
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Figure 3: Insulin sensitivity. Peripheral insulin sensitivity was assessed by intraperitoneal glucose tolerance tests represented as changes in
blood glucose over time (a), glucose area under the curve (AUC) (b), and insulin AUC (c). Values are means ± SE (n = 8). ∗EX is different
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livers, while markers of de novo lipogenesis (FAS and ACC
protein content and malonyl CoA) increased significantly 2
and 7 days after the cessation of exercise. Hepatic TAG did
not increase significantly 7 days after the cessation of exercise
and remained significantly lower than the content measured
in sedentary rats. Thus, these data suggest that some hepatic
adaptations to EX treatment are sustained and due to chronic
training while others are dependent on the effects of the last
bout.
Peripheral insulin resistance is strongly associated with
hepatic steatosis. Importantly, high levels of circulating
insulin activate SREBP-1c, a master regulator of lipid
synthesis. Here we report that EX had the most powerful
effects on reducing glucose and insulin levels during the
IPGTT. Similar to our previous reports of exercise preventing
the development of insulin resistance in the OLETF model
[9, 12, 34], here we demonstrate that exercise also can
be used as a treatment to improve insulin sensitivity. We
also originally hypothesized that EX or dietary n3PUFAs
would reduce the mature form of SREBP-1c and would
play a key role in downregulating fatty acid synthesis in
the liver [16, 18, 35–37]. In addition, we hypothesized
that n3PUFAs would activate PPARα and δ, as n3PUFAs
are known to be natural ligands and potent activators of
PPARs. Surprisingly, the mature, nuclear form of SREBP-
1c was not significantly altered by any of the treatments
and n3PUFAs did not potently increase expression or
protein content of PPARs. However, although there were
no changes in SREBP-1c, protein content of FAS and SCD-
1, its downstream targets, was dramatically reduced with
EX. It is possible that the trend for lowering of nuclear
SREBP-1c was enough to lower FAS and SCD-1 or that EX
8 Journal of Nutrition and Metabolism
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lowered these factors through other pathways. Through the
conversion of saturated fatty acids to monounsaturated fatty
acids, hepatic SCD-1 contributes to abnormal partitioning
of fatty acids by reducing FAO and increasing fatty acid
synthesis. EX significantly suppressed SCD-1 expression and
activity, resulting in lower desaturation of the fatty acid
within hepatic TAG which is consistent with our previous
results. In contrast, n3PUFA did not impact SCD-1 content
and slightly increased activity as shown by the desaturase
index. FAS is also a critical step in the conversion of
carbohydrates to fatty acids through de novo lipogenesis. All
told, EX lowered markers of hepatic lipogenesis, but because
this occurred without a clear lowering of nuclear SREBP-1c
content, we are unsure these changes are directly linked to
reduced circulating insulin and improved systemic insulin
sensitivity.
Contrary to our original hypothesis and the results of
others, we found that n3PUFA supplementation in SED
OLETFs led to increased TAG accumulation in the liver
[16, 19, 20, 35, 38]. Although our results are conflicting
with a large majority of the literature, it should be noted
that the majority of fish oil/n3PUFA research conducted
in animals uses excessive amounts (6–60% of energy) that
are not likely physiologically relevant [16, 35–41]. Here we
used a diet consisting of 3% of total energy from fish oil
which is a concentration that can safely be consumed by
humans [42]. Consequently, it may require higher dosages
of n3PUFAs to yield the health benefits found by others in
their rodent models. In addition, we started treatment at 13
weeks of age, an age where OLETFs several obesity-induced
comorbidities such as NAFLD, systemic insulin resistance,
and increased adiposity are present which may explain the
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differences seen between prevention and treatment with
n3PUFAs. An alternative and more probable explanation is
that dietary consumption of “healthy” fatty acids cannot
likely overcome a hyperphagic, chronic state of positive
energy balance and daily weight gain in sedentary rats.
Excess energy intake, regardless of the source, will likely
result in increased adiposity and ectopic fat storage if not
matched with increased energy expenditure. Rather, either
lowering total energy intake or increasing energy expenditure
is likely needed to effectively treat hepatic steatosis. Future
experiments are needed to determine if n3PUFA intake
would be more effective in reducing steatosis in animals in
which the rate of weight gain is reduced by limiting caloric
consumption. There are also human clinical implications
to these findings. If patients are in a constant positive
energy balance and continuing to gain weight, it is unlikely
that increasing dietary n3PUFA would lower hepatic fat
content.
In conclusion, our study documents the detrimental
effects of overeating while remaining sedentary on adiposity,
insulin sensitivity, hepatic mitochondrial function, and
hepatic steatosis. Moreover, these adverse events occurred
regardless of supplementing n3PUFAs in the diet. However,
daily exercise effectively treats hepatic steatosis in obese
OLETF rats in part by increasing hepatic mitochondrial
function and complete fatty acid oxidation, decreasing
activation of the lipid synthesis pathway, and improving
systemic insulin sensitivity. Furthermore, treatment with
n3PUFAs partially blunted the beneficial effects of exercise
in this hyperphagic animal model by unknown mecha-
nisms.
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